<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosntds</journal-id>
<journal-title-group>
<journal-title>PLOS Neglected Tropical Diseases</journal-title>
</journal-title-group>
<issn pub-type="epub">1935-2735</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pntd.0003749</article-id>
<article-id pub-id-type="publisher-id">PNTD-D-14-01311</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Flipse</surname>
<given-names>Jacky</given-names>
</name>
<xref rid="aff001" ref-type="aff"/>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Smit</surname>
<given-names>Jolanda M.</given-names>
</name>
<xref rid="cor001" ref-type="corresp">*</xref>
<xref rid="aff001" ref-type="aff"/>
</contrib>
</contrib-group>
<aff id="aff001"><addr-line>Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Simmons</surname>
<given-names>Cameron P.</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Oxford University Clinical Research Unit, VIETNAM</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">jolanda.smit@umcg.nl</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>6</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="collection">
<month>6</month>
<year>2015</year>
</pub-date>
<volume>9</volume>
<issue>6</issue>
<elocation-id>e0003749</elocation-id>
<permissions>
<copyright-year>2015</copyright-year>
<copyright-holder>Flipse, Smit</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pntd.0003749" xlink:type="simple"/>
<abstract>
<p>Dengue is the most prevalent mosquito-borne viral disease worldwide. Yet, there are no vaccines or specific antivirals available to prevent or treat the disease. Several dengue vaccines are currently in clinical or preclinical stages. The most advanced vaccine is the chimeric tetravalent CYD-TDV vaccine of Sanofi Pasteur. This vaccine has recently cleared Phase III, and efficacy results have been published. Excellent tetravalent seroconversion was seen, yet the protective efficacy against infection was surprisingly low. Here, we will describe the complicating factors involved in the generation of a safe and efficacious dengue vaccine. Furthermore, we will discuss the human antibody responses during infection, including the epitopes targeted in humans. Also, we will discuss the current understanding of the assays used to evaluate antibody response. We hope this review will aid future dengue vaccine development as well as fundamental research related to the phenomenon of antibody-dependent enhancement of dengue virus infection.</p>
</abstract>
<funding-group>
<funding-statement>JF and JMS acknowledge funding of the Dutch Organization for Scientific Research (NWO Vidi grant to JMS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="1"/>
<table-count count="2"/>
<page-count count="18"/>
</counts>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>The genus <italic>Flavivirus</italic> of the family <italic>Flaviviridae</italic> comprises over 50 closely related viruses, including dengue virus (DENV), Japanese encephalitis virus (JEV), yellow fever virus (YFV), tick-borne encephalitis virus (TBEV), and West Nile virus (WNV) (<xref rid="pntd.0003749.g001" ref-type="fig">Fig 1</xref>). Flaviviruses are arthropod-borne pathogens, and transmission occurs by ticks (TBEV) or mosquitoes (e.g., JEV and DENV). Flaviviruses are present worldwide, ranging from the tropics (JEV and DENV), to moderate climates (DENV and WNV), to near-arctic climate (TBEV) [<xref rid="pntd.0003749.ref001" ref-type="bibr">1</xref>].</p>
<fig id="pntd.0003749.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0003749.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Close relationship between several flaviviruses (left) and within the species of dengue virus (right).</title>
<p>The phylogenetic tree is based on the amino acid sequence of the envelope glycoproteins. The methodology and National Center for Biotechnology Information (NCBI) IDs of all used genotypes for the flaviviruses and dengue viruses are provided in <xref rid="pntd.0003749.s001" ref-type="supplementary-material">S1 Dataset</xref>. The table denominates the percentage of consensus between the serotypes based on the envelope amino acid sequences. Sequence identities were calculated using the Sequence Identity and Similarity (SIAS) calculator (<ext-link ext-link-type="uri" xlink:href="http://imed.med.ucm.es/Tools/sias.html" xlink:type="simple">http://imed.med.ucm.es/Tools/sias.html</ext-link>). Scale bar of 0.1 (flaviviruses) or 10 (dengue virus) denotes 0.1 or 10 (silent) substitutions per amino acid for the flavivirus and dengue sequences, respectively.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pntd.0003749.g001" position="float" xlink:type="simple"/>
</fig>
<p>Infection with a flavivirus can cause a wide range of clinically overt symptoms [<xref rid="pntd.0003749.ref001" ref-type="bibr">1</xref>,<xref rid="pntd.0003749.ref002" ref-type="bibr">2</xref>], potentially resulting in death. For example, JEV is the leading cause of viral encephalitis in Asia, with a 30%–40% case fatality rate [<xref rid="pntd.0003749.ref002" ref-type="bibr">2</xref>]. Dengue is the most common arthropod-borne viral infection occurring worldwide, with an estimated 360 million infections and 96 million symptomatic cases in 2010 [<xref rid="pntd.0003749.ref003" ref-type="bibr">3</xref>]. On average, 500,000–1 million individuals develop severe disease, including hemorrhage and plasma leakage, resulting in 25,000 deaths [<xref rid="pntd.0003749.ref004" ref-type="bibr">4</xref>].</p>
<p>Currently, there are vaccines available for YFV, TBEV, and JEV. Yet, there is no vaccine available for the closely related DENV [<xref rid="pntd.0003749.ref005" ref-type="bibr">5</xref>]. This is in part due to the existence of four genetically and antigenically distinct DENV serotypes (<xref rid="pntd.0003749.g001" ref-type="fig">Fig 1</xref>). There is approximately 40% divergence between the amino acid sequences of the serotypes (<xref rid="pntd.0003749.g001" ref-type="fig">Fig 1</xref>) [<xref rid="pntd.0003749.ref006" ref-type="bibr">6</xref>,<xref rid="pntd.0003749.ref007" ref-type="bibr">7</xref>] and up to ≤9% mismatch within a serotype (<xref rid="pntd.0003749.g001" ref-type="fig">Fig 1</xref>) [<xref rid="pntd.0003749.ref008" ref-type="bibr">8</xref>]. The diversity of the genotypes of JEV, WNV, and TBEV is much less, with ≤4.1%, ≤2%, and ≤5.6% difference, respectively [<xref rid="pntd.0003749.ref009" ref-type="bibr">9</xref>,<xref rid="pntd.0003749.ref010" ref-type="bibr">10</xref>]; therefore, no distinct serotypes exist.</p>
<p>Another factor for the complexity of the DENV vaccine lies in the severity of disease. All four DENV serotypes can cause symptoms ranging from acute febrile illness to severe manifestations as hemorrhage or organ impairment. Severe disease is most often seen during secondary, heterotypic reinfections [<xref rid="pntd.0003749.ref011" ref-type="bibr">11</xref>,<xref rid="pntd.0003749.ref012" ref-type="bibr">12</xref>]. The incidence of severe disease during secondary, heterologous infection relative to primary infection can be 20-fold to 80-fold higher [<xref rid="pntd.0003749.ref012" ref-type="bibr">12</xref>–<xref rid="pntd.0003749.ref015" ref-type="bibr">15</xref>]. The observation that disease can be more severe during secondary infections severely hampered the development of a vaccine, as it implies the need to simultaneously induce immunity to all four existing DENV serotypes over a prolonged period [<xref rid="pntd.0003749.ref016" ref-type="bibr">16</xref>,<xref rid="pntd.0003749.ref017" ref-type="bibr">17</xref>].</p>
<p>Multiple vaccine formulations are currently being tested in preclinical and clinical stages, and these have been reviewed before [<xref rid="pntd.0003749.ref018" ref-type="bibr">18</xref>]. Here, we will focus on the Sanofi Pasteur live attenuated vaccine since this is the most advanced vaccine with known efficacy results. The results of the trials will be reviewed and discussed within the context of the host immune response and the assays used to understand and evaluate both the vaccine and the host immune response.</p>
</sec>
<sec id="sec002">
<title>Sanofi Trials</title>
<p>Sanofi Pasteur developed a tetravalent chimeric YFV/DENV vaccine (CYD-TDV). The vaccine was based on the backbone of the attenuated YFV strain 17D in which the structural genes encoding for the premembrane (prM) and envelope (E) proteins of YFV were replaced with those of DENV [<xref rid="pntd.0003749.ref019" ref-type="bibr">19</xref>]. YFV/DENV chimeric viruses were made from all four DENV serotypes. The resulting viruses thus have the attenuated replication machinery of YFV and the outer structure of a DENV serotype. Hence, the vaccine induces CD4<sup>+</sup> T cell and antibody responses against the DENV structural proteins and CD8<sup>+</sup> T cell responses against the YFV nonstructural (NS) proteins [<xref rid="pntd.0003749.ref020" ref-type="bibr">20</xref>–<xref rid="pntd.0003749.ref022" ref-type="bibr">22</xref>]. Preclinical in vitro assays showed genomic stability and no toxicity (reviewed in [<xref rid="pntd.0003749.ref019" ref-type="bibr">19</xref>]) and induction of antiviral responses in human dendritic cells [<xref rid="pntd.0003749.ref023" ref-type="bibr">23</xref>].</p>
<p>Subsequently, clinical studies were performed using a three-dose regimen containing 10<sup>5</sup> CCID<sub>50</sub> of each YFV/DENV chimeric virus. The Phase I and II trials showed that the vaccine is safe and tolerable in humans [<xref rid="pntd.0003749.ref019" ref-type="bibr">19</xref>,<xref rid="pntd.0003749.ref024" ref-type="bibr">24</xref>], which was the primary end point. Additionally, the authors of the Phase II trials also determined the seroconversion and the efficacy against virologically confirmed DENV. In one study, excellent tetravalent seroconversion against DENV was noted, as 95%–100% of the individuals seroconverted [<xref rid="pntd.0003749.ref025" ref-type="bibr">25</xref>]. Yet, in the same study, the efficacy was surprisingly low, being 30%, whilst another study reported near 64% efficacy (<xref rid="pntd.0003749.t001" ref-type="table">Table 1</xref>). These Phase II trials were conducted with relatively low numbers of participants. Next, large Phase III trials were conducted in Asia and Latin America to determine the efficacy of the vaccine. However, the recent reports of these trials were quite enigmatic. The Phase III studies in Southeast Asia and South America reported an efficacy range of 51.1%–79% and 31.3%–77.5%, respectively. Overall, the vaccine was shown to be efficacious, as the 95% CI was higher than 25% (primary end point). It should be noted, however, that the reported efficacies varied per country and per study. Additionally, when the serotype specific efficacy was calculated, the lowest efficacy was consistently seen for DENV2 (<xref rid="pntd.0003749.t001" ref-type="table">Table 1</xref>).</p>
<table-wrap id="pntd.0003749.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0003749.t001</object-id>
<label>Table 1</label> <caption><title>An overview of the results from the CYD-TDV vaccine trials.</title></caption>
<alternatives>
<graphic id="pntd.0003749.t001g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pntd.0003749.t001" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1">Reference</th>
<th align="left" rowspan="1" colspan="1">Age Range (years)</th>
<th align="left" rowspan="1" colspan="1">Area</th>
<th colspan="3" align="center" rowspan="1">Efficacy</th>
<th colspan="2" align="center" rowspan="1">Baseline Immunity (%)</th>
<th align="left" rowspan="1" colspan="1">Effect of Baseline Immunity</th>
</tr>
<tr>
<th align="left" rowspan="1" colspan="1"/>
<th align="left" rowspan="1" colspan="1"/>
<th align="left" rowspan="1" colspan="1"/>
<th align="left" rowspan="1" colspan="1">Post Third Dose: Overall (95% CI).Serotype-Specific, DENV1/2/3/4</th>
<th align="left" rowspan="1" colspan="1">Hosp.</th>
<th align="left" rowspan="1" colspan="1">DHF</th>
<th align="left" rowspan="1" colspan="1">DENV</th>
<th align="left" rowspan="1" colspan="1">Flavi</th>
<th align="left" rowspan="1" colspan="1"/>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">[<xref rid="pntd.0003749.ref025" ref-type="bibr">25</xref>]</td>
<td align="left" rowspan="1" colspan="1">4–11</td>
<td align="left" rowspan="1" colspan="1">Thailand</td>
<td align="left" rowspan="1" colspan="1">30.2%(-13.4 to 56.6),55.6/9.2/75.3/100 <xref rid="t001fn002" ref-type="table-fn"><sup>†</sup></xref></td>
<td align="char" char="." rowspan="1" colspan="1"/>
<td align="char" char="." rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">69.9</td>
<td align="left" rowspan="1" colspan="1">91</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">[<xref rid="pntd.0003749.ref026" ref-type="bibr">26</xref>]</td>
<td align="left" rowspan="1" colspan="1">9–16</td>
<td align="left" rowspan="1" colspan="1">Honduras, Colombia, Mexico, and Puerto Rico</td>
<td align="left" rowspan="1" colspan="1">63.9% (1.5 to 87.4). <xref rid="t001fn002" ref-type="table-fn"><sup>†</sup></xref></td>
<td align="char" char="." rowspan="1" colspan="1"/>
<td align="char" char="." rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">76</td>
<td align="left" rowspan="1" colspan="1">79.3</td>
<td align="left" rowspan="1" colspan="1">Flavi<sup>+</sup> &gt; naïve (tetravalent: 97.6% versus 77.9%)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">[<xref rid="pntd.0003749.ref027" ref-type="bibr">27</xref>]</td>
<td align="left" rowspan="1" colspan="1">4–11</td>
<td align="left" rowspan="1" colspan="1">Indonesia, Malaysia, Philippine, Thailand, and Vietnam</td>
<td align="left" rowspan="1" colspan="1">56.5% (43.8 to 66.4).50/35/78.4/75.3</td>
<td align="char" char="." rowspan="1" colspan="1">67.2</td>
<td align="char" char="." rowspan="1" colspan="1">80.8</td>
<td align="left" rowspan="1" colspan="1">67.6</td>
<td align="left" rowspan="1" colspan="1">78.2</td>
<td align="left" rowspan="1" colspan="1">DENV<sup>+</sup> &gt; DENV<sup><bold>-</bold></sup> (efficacy: 74.3% versus 35.5%)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">[<xref rid="pntd.0003749.ref028" ref-type="bibr">28</xref>]</td>
<td align="left" rowspan="1" colspan="1">9–16</td>
<td align="left" rowspan="1" colspan="1">Colombia, Brazil, Mexico, Puerto Rico, and Honduras</td>
<td align="left" rowspan="1" colspan="1">60.8% (52.0 to 68.0).50.3/42.3/74/77.7</td>
<td align="char" char="." rowspan="1" colspan="1">80.3</td>
<td align="char" char="." rowspan="1" colspan="1">90.0</td>
<td align="left" rowspan="1" colspan="1">79.4</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">DENV<sup>+</sup> &gt; DENV<sup><bold>-</bold></sup> (efficacy: 83.7% versus 43.2%)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>95% CI, 95% confidence interval; Hosp., hospitalization; DHF, dengue hemorrhagic fever.</p></fn>
<fn id="t001fn002"><p><sup><bold>†</bold></sup> Study was a Phase II clinical trial, with a relatively low number of participants.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Strikingly, the vaccine cohort had significantly lower incidence of dengue hemorrhagic fever (80%–90% efficacy) and hospitalization (67%–80% efficacy) [<xref rid="pntd.0003749.ref027" ref-type="bibr">27</xref>,<xref rid="pntd.0003749.ref028" ref-type="bibr">28</xref>]. Baseline immunity seems to be beneficial in terms of developing tetravalent seroconversion and overall efficacy against symptomatic DENV (<xref rid="pntd.0003749.t001" ref-type="table">Table 1</xref>).</p>
<p>While the protection against hemorrhagic fever is encouraging, these trials also taught us that seroconversion alone does not predict protective efficacy. Clearly, more research is required to identify the correlate of protection [<xref rid="pntd.0003749.ref029" ref-type="bibr">29</xref>]. Furthermore, it showed us that we need to have a better understanding of the immune response to DENV infection. Hence, below we will discuss what is known about the function of T and B cells in immunity against DENV. Most attention has been directed towards the role of antibodies in immunity against DENV, and therefore, these will be the primary focus of this review.</p>
</sec>
<sec id="sec003">
<title>Human Immune Response and Disease</title>
<p>After a primary DENV infection, individuals are protected against disease upon reinfection with the homologous serotype. Cross-protection against other serotypes is limited and exists only for 1–2 months post–primary infection, while disease severity was found to be alleviated for 2–9 months thereafter [<xref rid="pntd.0003749.ref030" ref-type="bibr">30</xref>,<xref rid="pntd.0003749.ref031" ref-type="bibr">31</xref>]. Recent information suggests that cross-protection against severe disease lasts up to 2 years [<xref rid="pntd.0003749.ref032" ref-type="bibr">32</xref>–<xref rid="pntd.0003749.ref035" ref-type="bibr">35</xref>]. Intriguingly, after the cross-protective period, individuals are at risk of developing more severe dengue upon secondary infection with a heterotypic serotype. Moreover, the chance to develop severe disease increases with the time between the primary and the secondary infection [<xref rid="pntd.0003749.ref033" ref-type="bibr">33</xref>,<xref rid="pntd.0003749.ref034" ref-type="bibr">34</xref>].</p>
<p>The increased chance of severe disease can be explained by original antigenic sin, a phenomenon in which the human immune system preferentially activates memory T and B cells against the original antigen rather than instructing naïve T and B cells against the current antigen [<xref rid="pntd.0003749.ref036" ref-type="bibr">36</xref>,<xref rid="pntd.0003749.ref037" ref-type="bibr">37</xref>]. Indeed, it was found that upon a secondary heterotypic DENV infection, the acute T cell response is mostly directed towards the previous infecting serotype [<xref rid="pntd.0003749.ref038" ref-type="bibr">38</xref>,<xref rid="pntd.0003749.ref039" ref-type="bibr">39</xref>]. Over time, the T cells against conserved, cross-reactive epitopes are preferentially expanded, resulting in a DENV-broad [<xref rid="pntd.0003749.ref020" ref-type="bibr">20</xref>,<xref rid="pntd.0003749.ref038" ref-type="bibr">38</xref>,<xref rid="pntd.0003749.ref040" ref-type="bibr">40</xref>] and potentially flavivirus-broad response [<xref rid="pntd.0003749.ref039" ref-type="bibr">39</xref>,<xref rid="pntd.0003749.ref041" ref-type="bibr">41</xref>]. As for B cells, a predominant monotypic response with high avidity against the infecting serotype is observed 6–9 days after disease onset [<xref rid="pntd.0003749.ref042" ref-type="bibr">42</xref>,<xref rid="pntd.0003749.ref043" ref-type="bibr">43</xref>]. Yet, within 6 months of infection, a broad cross-reactive B cell repertoire is seen [<xref rid="pntd.0003749.ref043" ref-type="bibr">43</xref>]. Indeed, cross-reactive B cells are predominantly present at the time of secondary infection [<xref rid="pntd.0003749.ref042" ref-type="bibr">42</xref>]. These cells have been speculated to contribute to enhanced severity of dengue disease severity [<xref rid="pntd.0003749.ref044" ref-type="bibr">44</xref>] (discussed below). After a secondary heterotypic infection, stable populations of DENV-broad cross-reactive B cells are seen [<xref rid="pntd.0003749.ref042" ref-type="bibr">42</xref>,<xref rid="pntd.0003749.ref043" ref-type="bibr">43</xref>], and these cells secrete high levels of high-avidity antibodies [<xref rid="pntd.0003749.ref042" ref-type="bibr">42</xref>,<xref rid="pntd.0003749.ref045" ref-type="bibr">45</xref>,<xref rid="pntd.0003749.ref046" ref-type="bibr">46</xref>].</p>
<p>Antibodies are suggested to be more important than T cells in triggering the onset of severe disease. This was suggested because infants born to dengue immune mothers were noted to have a higher risk for severe disease development during primary infection [<xref rid="pntd.0003749.ref047" ref-type="bibr">47</xref>]. Halstead and others found that waning antibody titers can enhance DENV infectivity in vitro and in vivo [<xref rid="pntd.0003749.ref048" ref-type="bibr">48</xref>–<xref rid="pntd.0003749.ref050" ref-type="bibr">50</xref>] and developed the theory of antibody-dependent enhancement (ADE) of disease [<xref rid="pntd.0003749.ref048" ref-type="bibr">48</xref>,<xref rid="pntd.0003749.ref051" ref-type="bibr">51</xref>]. During ADE, the pre-existing cross-reactive antibodies bind to the newly infecting DENV serotype and specifically target the immune complexes to Fc-receptor-expressing cells, cells that are highly permissive to DENV. The high viral burden triggers the immune system, which at the end is responsible for the onset of severe signs like plasma leakage [<xref rid="pntd.0003749.ref051" ref-type="bibr">51</xref>–<xref rid="pntd.0003749.ref053" ref-type="bibr">53</xref>].</p>
<p>Thus, in case of dengue, antibodies have a paradoxical role: antibodies induced during a primary infection are believed to confer lifelong protection against the infecting serotype, whereas upon reinfection with another DENV serotype, these antibodies can contribute to severe disease development. Hence, we wished to gather information on the human antibody epitopes and their relative contributions to the human antibody repertoire after DENV vaccination and infection. Although we primarily focus on antibody epitopes, we also included a brief description of the role of T cells in connection with the CYD vaccine.</p>
<sec id="sec004">
<title>Human Antibody Responses</title>
<p>We first reviewed the antibody responses in the sera of primary and secondary DENV cases (<xref rid="pntd.0003749.s002" ref-type="supplementary-material">S1 Table</xref>). The majority of antibodies are raised against the E protein, and a small fraction target the prM and the NS proteins. This is not very surprising as E and prM are exposed on the viral surface and soluble NS1 is secreted by infected cells [<xref rid="pntd.0003749.ref054" ref-type="bibr">54</xref>]. The higher fraction of E protein antibodies suggests that the human antibody response predominantly targets DENV particles (structural proteins) rather than NS1-positive cells, i.e., infected cells or cells having bound soluble NS1 [<xref rid="pntd.0003749.ref055" ref-type="bibr">55</xref>,<xref rid="pntd.0003749.ref056" ref-type="bibr">56</xref>]. Interestingly, we see that during secondary infection the antibody repertoire broadens as higher responses against the prM and NS1 proteins are seen. This implies that antibodies against E, prM, and NS1 are differentially induced between primary and secondary infection (discussed further below). A detailed insight in the specific antibody repertoire may therefore help us to better understand the contribution of distinct epitopes to infection neutralization.</p>
<p>Indeed, several elegant studies have used immortalized B cells from human blood samples to generate monoclonal antibodies of these cultures. Unfortunately, the studies conducted so far show considerable variability in numbers and epitopes of antibodies isolated from individual patients (<xref rid="pntd.0003749.s003" ref-type="supplementary-material">S2 Table</xref>). This is likely due to differences in donor backgrounds and immortalizing method used. Therefore, we next focused on those studies in which primary and secondary antibody responses or acute and convalescent samples are compared (<xref rid="pntd.0003749.t002" ref-type="table">Table 2</xref>). Even then, the results are highly variable: e.g., the prM response strongly expands in two studies but decreased in one study. The latter study also showed a stable E response between primary and secondary responses, while the others reported a reduction thereof. Yet, when we looked at both sera and monoclonals (<xref rid="pntd.0003749.s002" ref-type="supplementary-material">S1</xref> and <xref rid="pntd.0003749.s003" ref-type="supplementary-material">S2</xref> Tables), overall, the E antibodies are dominant during the primary response. The results for secondary responses are more variable (<xref rid="pntd.0003749.t002" ref-type="table">Table 2</xref>), but in sera prM and NS antibodies are particularly detected in secondary cases (<xref rid="pntd.0003749.s002" ref-type="supplementary-material">S1 Table</xref>).</p>
<table-wrap id="pntd.0003749.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0003749.t002</object-id>
<label>Table 2</label> <caption><title>Temporal evaluation of human B cell-derived monoclonal antibodies against DENV.</title></caption>
<alternatives>
<graphic id="pntd.0003749.t002g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pntd.0003749.t002" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1">Reference</th>
<th align="left" rowspan="1" colspan="1">Stage</th>
<th align="left" rowspan="1" colspan="1"># Donors</th>
<th align="left" rowspan="1" colspan="1"># mAbs</th>
<th align="left" rowspan="1" colspan="1">NS1</th>
<th align="left" rowspan="1" colspan="1">prM</th>
<th align="left" rowspan="1" colspan="1">E</th>
<th colspan="2" align="center" rowspan="1">As % of Total E</th>
</tr>
<tr>
<th align="left" rowspan="1" colspan="1"/>
<th align="left" rowspan="1" colspan="1"/>
<th align="left" rowspan="1" colspan="1"/>
<th align="left" rowspan="1" colspan="1"/>
<th align="left" rowspan="1" colspan="1"/>
<th align="left" rowspan="1" colspan="1"/>
<th align="left" rowspan="1" colspan="1"/>
<th align="left" rowspan="1" colspan="1">EDI/DII</th>
<th align="left" rowspan="1" colspan="1">EDIII</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">[<xref rid="pntd.0003749.ref057" ref-type="bibr">57</xref>]</td>
<td align="left" rowspan="1" colspan="1">1st, convalescent</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">49</td>
<td align="left" rowspan="1" colspan="1">8.0%</td>
<td align="left" rowspan="1" colspan="1">5.7%</td>
<td align="left" rowspan="1" colspan="1">80.5%</td>
<td align="left" rowspan="1" colspan="1">72.6%</td>
<td align="left" rowspan="1" colspan="1">27.4%</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">2nd, convalescent</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">29</td>
<td align="left" rowspan="1" colspan="1">0.0%</td>
<td align="left" rowspan="1" colspan="1">2.6%</td>
<td align="left" rowspan="1" colspan="1">94.8%</td>
<td align="left" rowspan="1" colspan="1">75.0%</td>
<td align="left" rowspan="1" colspan="1">25.0%</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">[<xref rid="pntd.0003749.ref058" ref-type="bibr">58</xref>]</td>
<td align="left" rowspan="1" colspan="1">1st</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">28</td>
<td align="left" rowspan="1" colspan="1">n.d.</td>
<td align="left" rowspan="1" colspan="1">14.3%</td>
<td align="left" rowspan="1" colspan="1">85.7%</td>
<td align="left" rowspan="1" colspan="1">82.8%</td>
<td align="left" rowspan="1" colspan="1">17.2%</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">2nd</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">9</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">44.4%</td>
<td align="left" rowspan="1" colspan="1">55.6%</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">[<xref rid="pntd.0003749.ref059" ref-type="bibr">59</xref>]</td>
<td align="left" rowspan="1" colspan="1">2nd acute</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">121</td>
<td align="left" rowspan="1" colspan="1">3.3%</td>
<td align="left" rowspan="1" colspan="1">6.6%</td>
<td align="left" rowspan="1" colspan="1">81.8%</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">2nd, convalescent</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">15</td>
<td align="left" rowspan="1" colspan="1">53.3%</td>
<td align="left" rowspan="1" colspan="1">13.3%</td>
<td align="left" rowspan="1" colspan="1">13.3%</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>To generate the monoclonal antibodies (mAbs) listed in this table, peripheral blood mononuclear cells (PBMCs) had been taken after primary (1st) and secondary (2nd) infection or between the acute and convalescent phases. Note to table: in reports in which multiple donors had been used, all percentages were first calculated as % per donor and then averaged over all donors. Hence, some percentages in this table can differ from those in the reports in which the value is reported as the % of experiment rather than per donor. Not all antibodies were characterized; hence, values may be lower than 100%. n.d.: not determined. EDI/DII and DIII refer to the structural domains within the E ectodomain.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Furthermore, since binding of one epitope can enhance or diminish binding of antibodies against other epitopes [<xref rid="pntd.0003749.ref060" ref-type="bibr">60</xref>–<xref rid="pntd.0003749.ref062" ref-type="bibr">62</xref>], it would be interesting to see whether shifts in these ratios influence neutralization of DENV particles by antibodies against specific epitopes. Based on the tables, we tried to estimate the balance between the various targeted epitopes. For primary convalescent sera, a ratio of approximately 3 E antibodies to 1 prM antibody was found. In secondary convalescent cases, this was near 1 on 1.</p>
<p>Furthermore, the E protein consists of three ectodomains (D): E DI–DIII. In humans, DI and DII are immunodominant domains relative to DIII, as 3-fold more antibodies target DI/III than DIII. However, given the large variability, more studies are required to validate the results.</p>
<p>Although a significant proportion of antibodies target the NS proteins, DNA-vaccine trials suggest that these are not pivotal for neutralization of infection [<xref rid="pntd.0003749.ref063" ref-type="bibr">63</xref>,<xref rid="pntd.0003749.ref064" ref-type="bibr">64</xref>]. Yet, the NS1 antibodies may aid in clearance of infected cells [<xref rid="pntd.0003749.ref065" ref-type="bibr">65</xref>]. Here, we will focus on the antibodies that directly bind to the virus and discuss the clinical relevance of these antibodies.</p>
</sec>
<sec id="sec005">
<title>PrM Antibodies</title>
<p>We and others showed that prM antibodies are poorly neutralizing and highly enhancing [<xref rid="pntd.0003749.ref066" ref-type="bibr">66</xref>–<xref rid="pntd.0003749.ref070" ref-type="bibr">70</xref>]. Moreover, infection enhancement was seen over a broad range of concentrations, whereas neutralization occurred in a very narrow range and is incomplete [<xref rid="pntd.0003749.ref067" ref-type="bibr">67</xref>–<xref rid="pntd.0003749.ref070" ref-type="bibr">70</xref>]. Therefore, prM antibodies have been postulated to contribute primarily to antibody-dependent enhancement of dengue infection and severe disease development. Recent analysis, however, showed that although there is a robust prM response (20%–30%) during acute secondary DENV2 infection, there is no difference in the level of prM antibodies between mild and severe cases [<xref rid="pntd.0003749.ref071" ref-type="bibr">71</xref>]. Furthermore, prM antibody levels are increased during secondary, tertiary, and quaternary infections (<xref rid="pntd.0003749.t002" ref-type="table">Table 2</xref>, <xref rid="pntd.0003749.s003" ref-type="supplementary-material">S2 Table</xref>, and references therein), whereas severe disease is most often associated with secondary infection [<xref rid="pntd.0003749.ref072" ref-type="bibr">72</xref>]. Indeed, subsequent functional analysis did not show a specific correlation between the neutralization/enhancement profile of the sera towards prM-containing particles and the onset of severe disease [<xref rid="pntd.0003749.ref071" ref-type="bibr">71</xref>]. This suggests that prM antibodies are not a discriminating factor but act as a cofactor in disease development. Yet, given the weakly neutralizing properties of prM antibodies, it is advisable to avoid the presence of prM in vaccines.</p>
</sec>
<sec id="sec006">
<title>E Antibodies</title>
<p>Many studies have been done to link neutralization to certain epitopes or structural domains of the E protein (<xref rid="pntd.0003749.t002" ref-type="table">Table 2</xref>). Most of the antibodies were found to be directed against dengue EDII fusion loop (FL) (<xref rid="pntd.0003749.t002" ref-type="table">Table 2</xref>, <xref rid="pntd.0003749.s002" ref-type="supplementary-material">S1 Table</xref>, and references therein). Furthermore, Lai and colleagues found a correlation between serum EDII FL antibodies and the potency of the serum to neutralize heterotypic DENV [<xref rid="pntd.0003749.ref046" ref-type="bibr">46</xref>]. The relevance of these human EDII FL antibodies in protection was further strengthened by elegant tests using prM-E proteins or virus-like particles bearing mutations in the FL [<xref rid="pntd.0003749.ref046" ref-type="bibr">46</xref>,<xref rid="pntd.0003749.ref073" ref-type="bibr">73</xref>,<xref rid="pntd.0003749.ref074" ref-type="bibr">74</xref>].</p>
<p>Based on mouse models, the EDIII was initially considered a major antigen for the induction of serotype-specific neutralizing antibodies [<xref rid="pntd.0003749.ref075" ref-type="bibr">75</xref>,<xref rid="pntd.0003749.ref076" ref-type="bibr">76</xref>]. Surprisingly, quite low fractions of antibodies targeting EDIII were found during human infection [<xref rid="pntd.0003749.ref037" ref-type="bibr">37</xref>,<xref rid="pntd.0003749.ref077" ref-type="bibr">77</xref>], and similar low fractions were found after infection with other flaviviruses [<xref rid="pntd.0003749.ref078" ref-type="bibr">78</xref>–<xref rid="pntd.0003749.ref080" ref-type="bibr">80</xref>]. Moreover, depletion of EDIII-reactive antibodies showed that these are not absolutely required for neutralization [<xref rid="pntd.0003749.ref037" ref-type="bibr">37</xref>,<xref rid="pntd.0003749.ref078" ref-type="bibr">78</xref>,<xref rid="pntd.0003749.ref081" ref-type="bibr">81</xref>,<xref rid="pntd.0003749.ref082" ref-type="bibr">82</xref>].</p>
<p>This suggests that the neutralization potency is predominantly facilitated by antibodies against EDI, DII, and the FL. However, and importantly, some monoclonal antibodies could not bind to monomers of E or prM but still bound the whole virion [<xref rid="pntd.0003749.ref057" ref-type="bibr">57</xref>,<xref rid="pntd.0003749.ref058" ref-type="bibr">58</xref>,<xref rid="pntd.0003749.ref068" ref-type="bibr">68</xref>,<xref rid="pntd.0003749.ref081" ref-type="bibr">81</xref>,<xref rid="pntd.0003749.ref083" ref-type="bibr">83</xref>]. These antibodies may interact with quaternary structures [<xref rid="pntd.0003749.ref083" ref-type="bibr">83</xref>–<xref rid="pntd.0003749.ref085" ref-type="bibr">85</xref>] and effectively freeze the virus particle as it inhibits changes within the E protein that are required for fusion. An example of such quaternary structure is the EDI/DII hinge region, and recently, antibodies targeting this region were found to be serotype-specific and neutralizing [<xref rid="pntd.0003749.ref069" ref-type="bibr">69</xref>,<xref rid="pntd.0003749.ref084" ref-type="bibr">84</xref>,<xref rid="pntd.0003749.ref085" ref-type="bibr">85</xref>]. Antibodies that bind to viral particles but not to protein monomers are potently neutralizing [<xref rid="pntd.0003749.ref058" ref-type="bibr">58</xref>,<xref rid="pntd.0003749.ref069" ref-type="bibr">69</xref>,<xref rid="pntd.0003749.ref083" ref-type="bibr">83</xref>] but appear to be rare [<xref rid="pntd.0003749.ref066" ref-type="bibr">66</xref>]. A recent report, however, showed that near 40% of the isolated monoclonal antibodies (mAbs) bind to quaternary structures [<xref rid="pntd.0003749.ref083" ref-type="bibr">83</xref>]. To conclude, we see that the DENV E domains I/II are more immunodominant than the EDIII in terms of induction of antibodies in humans. Importantly, both EDI/II and EDIII antibodies were found to possess a similar neutralization potency [<xref rid="pntd.0003749.ref086" ref-type="bibr">86</xref>], and the most neutralizing antibodies against flaviviruses appear to target quaternary structures [<xref rid="pntd.0003749.ref078" ref-type="bibr">78</xref>,<xref rid="pntd.0003749.ref080" ref-type="bibr">80</xref>,<xref rid="pntd.0003749.ref083" ref-type="bibr">83</xref>,<xref rid="pntd.0003749.ref086" ref-type="bibr">86</xref>], These findings argue for preservation of quaternary structures in DENV vaccines.</p>
</sec>
<sec id="sec007">
<title>T Cells</title>
<p>The role of T cells in immunity against dengue infection has been extensively reviewed by others [<xref rid="pntd.0003749.ref052" ref-type="bibr">52</xref>,<xref rid="pntd.0003749.ref087" ref-type="bibr">87</xref>], and we will briefly discuss recent findings regarding the role of T cells in immunity and pathogenesis. Whereas the CD4<sup>+</sup> T cell response contributes to protection by instructing B cell responses against the virus [<xref rid="pntd.0003749.ref021" ref-type="bibr">21</xref>], the importance of cytotoxic (CD8<sup>+</sup>) T cells for protection is still under debate since low T cell responses are seen during acute stages of DENV infection [<xref rid="pntd.0003749.ref036" ref-type="bibr">36</xref>]. After peak viremia, peaks in both T cell response and cytokines are seen [<xref rid="pntd.0003749.ref036" ref-type="bibr">36</xref>,<xref rid="pntd.0003749.ref088" ref-type="bibr">88</xref>], suggesting that cross-reactive CD8<sup>+</sup> T cells contribute to pathogenesis rather than protection. Furthermore, during secondary infection, T cells (like B cells) suffer from original antigenic sin [<xref rid="pntd.0003749.ref022" ref-type="bibr">22</xref>,<xref rid="pntd.0003749.ref036" ref-type="bibr">36</xref>,<xref rid="pntd.0003749.ref089" ref-type="bibr">89</xref>]. The cross-reactive T cells during acute secondary infection have an altered cytokine responses consisting of low interferon gamma (IFN-γ) and high tumor necrosis factor alpha (TNF-α) [<xref rid="pntd.0003749.ref088" ref-type="bibr">88</xref>,<xref rid="pntd.0003749.ref090" ref-type="bibr">90</xref>]. This profile has been associated with severe disease [<xref rid="pntd.0003749.ref052" ref-type="bibr">52</xref>]. The phenomenon of original antigenic sin might be less persistent in T cells than in B cells [<xref rid="pntd.0003749.ref020" ref-type="bibr">20</xref>], as a recent manuscript showed that multifunctional CD8<sup>+</sup> T cells can be associated with protection against disease in a Sri Lankan population [<xref rid="pntd.0003749.ref022" ref-type="bibr">22</xref>].</p>
<p>Clearly, in naïve individuals, the CYD-TDV vaccine does not induce CD8<sup>+</sup> T cell responses to the NS proteins of DENV. The participants in the CYD trials, however, had high baseline immunity, implying that T cell responses were already present and potentially boosted by the vaccine [<xref rid="pntd.0003749.ref020" ref-type="bibr">20</xref>,<xref rid="pntd.0003749.ref039" ref-type="bibr">39</xref>,<xref rid="pntd.0003749.ref041" ref-type="bibr">41</xref>]. Thus, we cannot conclude whether or not it is important to include T cell immunity for protection and if this should be induced by a vaccine. Yet, the trials had quite low efficacy results despite high antibody titers. Mouse models indicated that protection requires both B and T cells [<xref rid="pntd.0003749.ref091" ref-type="bibr">91</xref>] and that CD8<sup>+</sup> T cells significantly contribute to disease alleviation, even under conditions of ADE [<xref rid="pntd.0003749.ref092" ref-type="bibr">92</xref>]. Thus, CD8<sup>+</sup> T cells likely contribute to clearance of infection when antibodies have failed to prevent infection. Hence, T cells might be more important for DENV immunity than previously appraised.</p>
</sec>
</sec>
<sec id="sec008">
<title>Assays for Vaccine Development</title>
<p>Seroconversion upon vaccination is measured with various assays based on either quantification of DENV-binding antibodies (ELISA) or bioassays measuring neutralization of infection [<xref rid="pntd.0003749.ref093" ref-type="bibr">93</xref>]. Currently, the WHO considers the plaque reduction neutralization test (PRNT), which is validated to industrial standards, as the gold standard for DENV [<xref rid="pntd.0003749.ref093" ref-type="bibr">93</xref>]. In case of the latter, DENV is mixed with serially diluted sera and added to a monolayer of cells. After incubation, an overlay is placed on top of the cells and plaques develop over time. The neutralization potency of the sera is defined as the dilution that neutralized 50% or 90% of the added virions. For JEV, the correlate of protection is 50% neutralization at a dilution of 1:10 or lower (PRNT<sub>50</sub> titer of ≥10), and similar correlates of protection have been defined for TBEV and YFV [<xref rid="pntd.0003749.ref094" ref-type="bibr">94</xref>]. For DENV, the exact cutoff is unknown but was expected to be similar to the viruses mentioned above.</p>
<p>Based on these criteria, the CYD-TDV trials showed good seroconversion rates, yet for DENV2 a particularly low clinical efficacy was seen (<xref rid="pntd.0003749.t002" ref-type="table">Table 2</xref>). This shows that the PRNT assay or its interpretation requires further fine tuning in order to find the true correlate of protection. Many parameters can be adjusted [<xref rid="pntd.0003749.ref095" ref-type="bibr">95</xref>–<xref rid="pntd.0003749.ref097" ref-type="bibr">97</xref>], such as (I) the cell line, (II) the challenge virus strain, and (III) the defined cutoff for seropositivity. Other parameters include incubation temperature [<xref rid="pntd.0003749.ref098" ref-type="bibr">98</xref>,<xref rid="pntd.0003749.ref099" ref-type="bibr">99</xref>] and virus source [<xref rid="pntd.0003749.ref083" ref-type="bibr">83</xref>].</p>
<p>The current PRNT assay employs the Vero cells, an Fc-receptor (FcR)-negative cell line. FcR-negative cells are inclined toward neutralization, as virus-antibody complexes are only internalized via interaction with FcR. Conversely, FcR-positive cells typically show ADE with poor neutralization [<xref rid="pntd.0003749.ref050" ref-type="bibr">50</xref>]. Primary myeloid cells are a natural host cell of DENV and support infection in the absence and presence of antibodies, and they could be an alternative to cell lines [<xref rid="pntd.0003749.ref100" ref-type="bibr">100</xref>]. As a start, it would be interesting to investigate if neutralization assays performed with PBMCs of vaccinees gives a better correlate of protection than that of Vero cells. It is unlikely that primary cells will be applied in an industrial setting; yet, the above studies will guide future assay development.</p>
<p>Second, distinct DENV genotypes can give significant shifts in the reported seropositivity, giving e.g. 50% reduction [<xref rid="pntd.0003749.ref072" ref-type="bibr">72</xref>]. This is not surprising given the 9% variation within a serotype (<xref rid="pntd.0003749.g001" ref-type="fig">Fig 1</xref>). More robust correlates of protection against a serotype could be found by including multiple genotypes reflecting the breadth within the serotype.</p>
<p>Third, the threshold chosen for seropositivity was a PRNT<sub>50</sub> of 10. Yet, the threshold of 50% reduction may not be optimal in terms of variability [<xref rid="pntd.0003749.ref097" ref-type="bibr">97</xref>], and different thresholds may be needed according to the serotype [<xref rid="pntd.0003749.ref101" ref-type="bibr">101</xref>]. Indeed, in case of the JEV vaccines, the PRNT<sub>50</sub> values were found to differ between the existing genotypes [<xref rid="pntd.0003749.ref102" ref-type="bibr">102</xref>]. The DENV vaccine cohorts now provide excellent opportunities to conduct mathematical studies to find better correlates of protection using more stringent criteria for the neutralization threshold and/or serum dilution.</p>
<p>Overall, there is a poor correlation between the current cutoff for seropositivity (PRNT<sub>50</sub> ≥10) and clinical efficacy of a DENV vaccine [<xref rid="pntd.0003749.ref025" ref-type="bibr">25</xref>,<xref rid="pntd.0003749.ref103" ref-type="bibr">103</xref>]. Since Sanofi will continue to monitor the vaccine participants for the next 4 years [<xref rid="pntd.0003749.ref019" ref-type="bibr">19</xref>,<xref rid="pntd.0003749.ref027" ref-type="bibr">27</xref>,<xref rid="pntd.0003749.ref028" ref-type="bibr">28</xref>], the present vaccine trials now offer new prospects for studies to define the best assay and criteria that predict which vaccinees have developed protective immunity. Future studies will also benefit from the lesson of these trials, i.e., that too few participants were bled to allow for thorough correlative analysis between the antibody response and individual protection [<xref rid="pntd.0003749.ref028" ref-type="bibr">28</xref>].</p>
</sec>
<sec id="sec009">
<title>Challenges for Future Dengue Vaccines</title>
<p>In this review, we briefly summarized the outcome of the CYD-TDV vaccine trials. The trials showed us that seroconversion of vaccinees does not necessarily correlate to clinical efficacy against symptomatic disease. This stressed how little we actually know about the human adaptive immune responses towards DENV infection. Most attention had been paid to the human antibody response, and the components thereof have been reviewed above (<xref rid="pntd.0003749.t002" ref-type="table">Table 2</xref> and <xref rid="pntd.0003749.s002" ref-type="supplementary-material">S1 Table</xref>). Based on the Sanofi trials and the reports on the human antibody response, some challenging questions are discussed below.</p>
<sec id="sec010">
<title>Better Responses after Flavivirus Priming?</title>
<p>The CYD-TDV trials reported higher antibody titers in individuals who were flavivirus-positive at baseline than in naïve individuals [<xref rid="pntd.0003749.ref020" ref-type="bibr">20</xref>,<xref rid="pntd.0003749.ref026" ref-type="bibr">26</xref>,<xref rid="pntd.0003749.ref104" ref-type="bibr">104</xref>]. Also, priming apparently gives higher chance on tetravalency [<xref rid="pntd.0003749.ref020" ref-type="bibr">20</xref>,<xref rid="pntd.0003749.ref026" ref-type="bibr">26</xref>] and better efficacy [<xref rid="pntd.0003749.ref027" ref-type="bibr">27</xref>,<xref rid="pntd.0003749.ref028" ref-type="bibr">28</xref>]. The better efficacy results in primed individuals suggests that the immune response is different in naïve and primed individuals. In naive individuals, only the DENV antibody response is triggered by CYD-TDV, while in primed individuals, B and T cell responses are boosted, the latter likely through flavivirus-broad conserved epitopes. Yet, the lower antibody levels in flavivirus-naïve individuals could not be compensated for by repeated vaccination [<xref rid="pntd.0003749.ref026" ref-type="bibr">26</xref>]. This raises the question of whether the vaccine preferentially expands pre-existing (cross-reactive) immunity and weakly induces de novo immunity. If so, the vaccine may be less beneficial for young children in endemic countries and travelers.</p>
</sec>
<sec id="sec011">
<title>Absolute Requirement for Tetravalency?</title>
<p>The current dogma is that vaccination should induce serotype-specific antibodies against all four DENV serotypes. Pierson and colleagues suggested that all antibodies that can bind and neutralize DENV can also promote enhancement of infection, irrespective of the epitope [<xref rid="pntd.0003749.ref105" ref-type="bibr">105</xref>]. If all antibodies support ADE and neutralization, high titers of cross-reactive antibodies may be sufficient for protection. Yet, a recent study showed that inapparent and apparent dengue cases have similar DENV–immunoglobulin G (IgG) titers but can be distinguished based on whether the sera shows heterotypic neutralizing capacity or not [<xref rid="pntd.0003749.ref106" ref-type="bibr">106</xref>]. Future studies should address whether protection of infection depends on the balance of monotypic antibodies and heterotypic antibodies and/or the cumulative titer of all DENV antibodies.</p>
</sec>
<sec id="sec012">
<title>Why Low Efficacy towards DENV2?</title>
<p>The CYD-TDV showed excellent seroconversion but did not result in high efficacy against symptomatic DENV2. The lack of CD8<sup>+</sup> T cell responses has been suggested as an option [<xref rid="pntd.0003749.ref022" ref-type="bibr">22</xref>]. Recently, there is also growing awareness about the role of the genotype used within the vaccine. Various genotypes of the same serotype can co-currently circulate within endemic areas [<xref rid="pntd.0003749.ref107" ref-type="bibr">107</xref>,<xref rid="pntd.0003749.ref108" ref-type="bibr">108</xref>]. A mismatch in the genotypes can significantly reduce the affinity of the sera to neutralize infection [<xref rid="pntd.0003749.ref072" ref-type="bibr">72</xref>] or may even lead to ADE [<xref rid="pntd.0003749.ref007" ref-type="bibr">7</xref>,<xref rid="pntd.0003749.ref008" ref-type="bibr">8</xref>]. The low efficacy against DENV2 in the Thai Phase IIb trial was suggested to have occurred because of a mismatch in the vaccine genotype and the circulating genotype [<xref rid="pntd.0003749.ref025" ref-type="bibr">25</xref>,<xref rid="pntd.0003749.ref109" ref-type="bibr">109</xref>]. If mismatches are indeed important, close surveillance and prediction of the circulating genotypes is crucial. Annual reformulation may be beneficial for protection.</p>
</sec>
<sec id="sec013">
<title>Vaccine Formulation</title>
<p>The formulation and administration regime of the ideal vaccine is a challenging topic. Subunit vaccines with monomer proteins are safe and can be easily reformulated. However, subunit vaccines also induce antibodies against epitopes that are inaccessible on virus particles due to protein-protein interactions [<xref rid="pntd.0003749.ref110" ref-type="bibr">110</xref>] and lack quaternary structures, which are currently the most potent epitopes for neutralization [<xref rid="pntd.0003749.ref058" ref-type="bibr">58</xref>,<xref rid="pntd.0003749.ref069" ref-type="bibr">69</xref>]. Induction of antibodies against quaternary structures could be facilitated by using whole inactivated viruses, attenuated virus strains, or chimeric viruses.</p>
<p>These three options have their pros and cons. Inactivated vaccines are noninfectious and may induce lower titers of neutralizing antibody compared with vaccines or infection [<xref rid="pntd.0003749.ref066" ref-type="bibr">66</xref>,<xref rid="pntd.0003749.ref078" ref-type="bibr">78</xref>], likely since different gene expression patterns are induced [<xref rid="pntd.0003749.ref023" ref-type="bibr">23</xref>,<xref rid="pntd.0003749.ref111" ref-type="bibr">111</xref>]. Lastly, attenuated virus strains mimic the actual pathogen as closely as possible, have the desired quaternary structures, and can induce high antibody titers. Yet, the chimeric vaccine lacks DENV-specific CD8<sup>+</sup> T cell responses. Moreover, attenuated vaccines can mutate after administration and potentially become virulent, causing health risks, e.g., as seen in polio virus vaccines [<xref rid="pntd.0003749.ref112" ref-type="bibr">112</xref>,<xref rid="pntd.0003749.ref113" ref-type="bibr">113</xref>]. So far, the results of the Sanofi trials show that the attenuated CYD vaccine is very safe, with no evidence of ADE. Follow-up monitoring of these and future cohorts is important to show that the vaccine is safe over prolonged time periods [<xref rid="pntd.0003749.ref019" ref-type="bibr">19</xref>]. The paradox of a DENV vaccine is thus that a vaccine should be sufficiently virulent to induce high antibody titers yet still be attenuated to be safe.</p>
<p>In summary, the recent Phase III trials showed safety and excellent seroconversion [<xref rid="pntd.0003749.ref024" ref-type="bibr">24</xref>], although seroconversion did not necessarily imply good efficacy, as shown by DENV2. A major challenge for the future would be to define what assay and criteria predict successful immunization and clinical efficacy. Still, the CYD-TDV offers promise to prevent hospitalization and severe dengue hemorrhagic fever, which is encouraging news. These CYD-TDV trials offer plenty of clues to gain more knowledge about the human response against DENV, the cross-reactivity with and potential cross-protection against flaviviruses, and the interpretation of antibody-based neutralization assays. Knowledge on this will aid future vaccine development against other viruses and pathogens than DENV.</p>
<boxed-text id="pntd.0003749.box001" position="float">
<sec id="sec014">
<title>Key Learning Points</title>
<list list-type="bullet">
<list-item><p>Vaccines should preferably induce antibodies against quaternary structures.</p></list-item>
<list-item><p>Distinct antibody repertoires are seen for primary and secondary infections.</p></list-item>
<list-item><p>The CYD-TDV trials offer possibilities for retrospective analysis to identify correlates of protection.</p></list-item>
<list-item><p>To find correlates of protection, further validation and standardization of neutralization assays is required.</p></list-item>
<list-item><p>T cells could be more important in DENV immunity than previously appreciated.</p></list-item>
</list>
</sec>
</boxed-text>
<boxed-text id="pntd.0003749.box002" position="float">
<sec id="sec015">
<title>Top Papers in the Field</title>
<list list-type="bullet">
<list-item><p>Halstead SB, O'Rourke EJ (1977) Dengue Viruses and Mononuclear Phagocytes. I. Infection Enhancement by Non-neutralizing Antibody. J Exp Med 146: 201–217.</p></list-item>
</list>
<disp-quote>
<p><italic>One of the earliest papers raising awareness on the paradoxical role of antibodies in dengue disease</italic>.</p>
</disp-quote>
<list list-type="bullet">
<list-item><p>Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, et al. (2014) Clinical Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children in Asia: A Phase 3, Randomized Observer-Masked Placebo-Controlled Trial. Lancet 384: 1358–1365.</p></list-item>
<list-item><p>Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, et al. (2014) Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America. N Engl J Med 372: 113–123.</p></list-item>
<list-item><p>Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, et al. (2012) Protective Efficacy of the Recombinant, Live-Attenuated, CYD Tetravalent Dengue Vaccine in Thai Schoolchildren: A Randomized, Controlled Phase 2b Trial. Lancet 380: 1559–1567.</p></list-item>
</list>
<disp-quote>
<p><italic>In these reports</italic>, <italic>the efficacies of the CYD-TDV vaccines are reported for the first time</italic>, <italic>based on large cohorts in Asia and Latin America</italic>. <italic>Although the efficacy against DENV2 is quite enigmatic</italic>, <italic>the overall efficacy against severe disease and hospitalization offers perspective</italic>.</p>
</disp-quote>
<list list-type="bullet">
<list-item><p>de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, et al. (2012) Identification of Human Neutralizing Antibodies That Bind to Complex Epitopes on Dengue Virions. Proc Natl Acad Sci U S A 109: 7439–7444.</p></list-item>
</list>
<disp-quote>
<p><italic>Here</italic>, <italic>the authors show that potently neutralizing antibodies appear to be directed towards quaternary structures</italic>, <italic>thus providing insight on the requirements of a dengue vaccine</italic>.</p>
</disp-quote>
<list list-type="bullet">
<list-item><p>Zellweger RM, Miller R, Eddy WE, White LJ, Johnston RE, et al. (2013) Role of Humoral Versus Cellular Responses Induced by a Protective Dengue Vaccine Candidate. PLoS Pathog 9: e1003723.</p></list-item>
</list>
<disp-quote>
<p><italic>This paper shows the importance of T cells in immunity against dengue virus infections</italic>, <italic>clearly advocating against a focus on antibodies alone</italic>.</p>
</disp-quote>
<list list-type="bullet">
<list-item><p>Salje H, Rodriguez-Barraquer I, Rainwater-Lovett K, Nisalak A, Thaisomboonsuk B, et al. (2014) Variability in Dengue Titer Estimates from Plaque Reduction Neutralization Tests Poses a Challenge to Epidemiological Studies and Vaccine Development. PLoS Negl Trop Dis 8: e2952</p></list-item>
</list>
<disp-quote>
<p><italic>The translation from in vitro plaque reduction neutralization assays to in vivo protection has been seriously hampered by the lack of uniformity in the assays and controls</italic>. <italic>With this paper</italic>, <italic>the authors are providing insight on the variance of the assays and definitions of neutralization</italic>. <italic>Moreover</italic>, <italic>clear solutions are suggested for the standardization thereof</italic>.</p>
</disp-quote>
</sec>
</boxed-text>
</sec>
</sec>
<sec id="sec016">
<title>Supporting Information</title>
<supplementary-material id="pntd.0003749.s001" xlink:href="info:doi/10.1371/journal.pntd.0003749.s001" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:type="simple">
<label>S1 Dataset</label>
<caption>
<title>E amino acid sequences used in the review.</title>
<p>The information is given as follows: country of isolation_strain_year of isolation (if known).</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pntd.0003749.s002" xlink:href="info:doi/10.1371/journal.pntd.0003749.s002" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>An overview of the dengue antibody response in human sera.</title>
<p>In this table, the focus is on the development after primary (1st) and secondary (2nd) infection, with the stage of disease at the moment of serum sampling being convalescent (conv.) or unknown. If unknown, only the stage is presented. We grouped the results of primary and secondary infections for individual reports in order to visualize the effects of secondary infection on the antigens targeted and the relative magnitude of antibodies against the epitopes. m.p.i.: months post infection. n.d.: Not determined.</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pntd.0003749.s003" xlink:href="info:doi/10.1371/journal.pntd.0003749.s003" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:type="simple">
<label>S2 Table</label>
<caption>
<title>An overview of human monoclonal antibodies derived from immortalized B cells.</title>
<p>An overview of human B cell-derived monoclonal antibodies from dengue-infected humans whose PBMCs were taken after primary (1st) or secondary (2nd) infection. The stage of disease was either acute (ac) or convalescent (conv.). Note to table: in reports in which multiple donors had been used, all percentages are first calculated as % per donor and then averaged over all donors. Hence, some percentages can differ from reports in which the value is reported as % of the whole experiment. n.d.: not determined. EDI/DII and DIII refer to the structural domains within the E ectodomain. Reports were selected based on whether they (I) were the first to describe the monoclonal antibodies, (II) screened against several epitopes, and (III) used an unbiased approach to generate the monoclonals.</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We apologize to those whose seminal contributions we could not cite because of space restrictions. We thank Dr. Adriana Tami-Grundman for her help and the reviewers for their suggestions and contributions.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pntd.0003749.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sips</surname> <given-names>GJ</given-names></name>, <name name-style="western"><surname>Wilschut</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Smit</surname> <given-names>JM</given-names></name>. <article-title>Neuroinvasive flavivirus infections</article-title>. <source>Rev Med Virol</source>. <year>2012</year>;<volume>22</volume>: <fpage>69</fpage>–<lpage>87</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/rmv.712" xlink:type="simple">10.1002/rmv.712</ext-link></comment> <object-id pub-id-type="pmid">22086854</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref002"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">European Centre for Disease Prevention and Control. Annual epidemiological report 2012.guidelines for the surveillance of invasive mosquitoes in Europe.stockholm: ECDC; 2012</mixed-citation></ref>
<ref id="pntd.0003749.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bhatt</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Gething</surname> <given-names>PW</given-names></name>, <name name-style="western"><surname>Brady</surname> <given-names>OJ</given-names></name>, <name name-style="western"><surname>Messina</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Farlow</surname> <given-names>AW</given-names></name>, <name name-style="western"><surname>Moyes</surname> <given-names>CL</given-names></name>, <etal>et al</etal>. <article-title>The global distribution and burden of dengue</article-title>. <source>Nature</source>. <year>2013</year>;<volume>496</volume>: <fpage>504</fpage>–<lpage>507</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature12060" xlink:type="simple">10.1038/nature12060</ext-link></comment> <object-id pub-id-type="pmid">23563266</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gubler</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Meltzer</surname> <given-names>M</given-names></name>. <article-title>Impact of dengue/dengue hemorrhagic fever on the developing world</article-title>. <source>Adv Virus Res</source>. <year>1999</year>;<volume>53</volume>: <fpage>35</fpage>–<lpage>70</lpage>. <object-id pub-id-type="pmid">10582094</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref005"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization. Fact sheet: Dengue and severe dengue. Http://<ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs117/en/index.html" xlink:type="simple">www.who.int/mediacentre/factsheets/fs117/en/index.html</ext-link>. 2012;March 2013: 1.</mixed-citation></ref>
<ref id="pntd.0003749.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Heinz</surname> <given-names>FX</given-names></name>, <name name-style="western"><surname>Stiasny</surname> <given-names>K</given-names></name>. <article-title>Flaviviruses and flavivirus vaccines</article-title>. <source>Vaccine</source>. <year>2012</year>;<volume>30</volume>: <fpage>4301</fpage>–<lpage>4306</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.vaccine.2011.09.114" xlink:type="simple">10.1016/j.vaccine.2011.09.114</ext-link></comment> <object-id pub-id-type="pmid">22682286</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brien</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Austin</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Sukupolvi-Petty</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>O'Brien</surname> <given-names>KM</given-names></name>, <name name-style="western"><surname>Johnson</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Fremont</surname> <given-names>DH</given-names></name>, <etal>et al</etal>. <article-title>Genotype-specific neutralization and protection by antibodies against dengue virus type 3</article-title>. <source>J Virol</source>. <year>2010</year>;<volume>84</volume>: <fpage>10630</fpage>–<lpage>10643</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.01190-10" xlink:type="simple">10.1128/JVI.01190-10</ext-link></comment> <object-id pub-id-type="pmid">20702644</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wahala</surname> <given-names>WM</given-names></name>, <name name-style="western"><surname>Donaldson</surname> <given-names>EF</given-names></name>, <name name-style="western"><surname>de Alwis</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Accavitti-Loper</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Baric</surname> <given-names>RS</given-names></name>, <name name-style="western"><surname>de Silva</surname> <given-names>AM</given-names></name>. <article-title>Natural strain variation and antibody neutralization of dengue serotype 3 viruses</article-title>. <source>PLoS Pathog</source>. <year>2010</year>;<volume>6</volume>: <fpage>e1000821</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.ppat.1000821" xlink:type="simple">10.1371/journal.ppat.1000821</ext-link></comment> <object-id pub-id-type="pmid">20333252</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ecker</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Allison</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Meixner</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Heinz</surname> <given-names>FX</given-names></name>. <article-title>Sequence analysis and genetic classification of tick-borne encephalitis viruses from europe and asia</article-title>. <source>J Gen Virol</source>. <year>1999</year>;<volume>80</volume> (Pt <issue>1</issue>): <fpage>179</fpage>–<lpage>185</lpage>.</mixed-citation></ref>
<ref id="pntd.0003749.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sotelo</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Fernandez-Pinero</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Llorente</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Vazquez</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Moreno</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Aguero</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Phylogenetic relationships of western mediterranean west nile virus strains (1996–2010) using full-length genome sequences: Single or multiple introductions?</article-title> <source>J Gen Virol</source>. <year>2011</year>;<volume>92</volume>: <fpage>2512</fpage>–<lpage>2522</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1099/vir.0.033829-0" xlink:type="simple">10.1099/vir.0.033829-0</ext-link></comment> <object-id pub-id-type="pmid">21775579</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Burke</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Nisalak</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Johnson</surname> <given-names>DE</given-names></name>, <name name-style="western"><surname>Scott</surname> <given-names>RM</given-names></name>. <article-title>A prospective study of dengue infections in bangkok</article-title>. <source>Am J Trop Med Hyg</source>. <year>1988</year>;<volume>38</volume>: <fpage>172</fpage>–<lpage>180</lpage>. <object-id pub-id-type="pmid">3341519</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mizumoto</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Ejima</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Yamamoto</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Nishiura</surname> <given-names>H</given-names></name>. <article-title>On the risk of severe dengue during secondary infection: A systematic review coupled with mathematical modeling</article-title>. <source>J Vector Borne Dis</source>. <year>2014</year>;<volume>51</volume>: <fpage>153</fpage>–<lpage>164</lpage>. <object-id pub-id-type="pmid">25253207</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Halstead</surname> <given-names>SB</given-names></name>. <article-title>Immune enhancement of viral infection</article-title>. <source>Prog Allergy</source>. <year>1982</year>;<volume>31</volume>: <fpage>301</fpage>–<lpage>364</lpage>. <object-id pub-id-type="pmid">6292921</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Russell</surname> <given-names>PK</given-names></name>, <name name-style="western"><surname>Yuill</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Nisalak</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Udomsakdi</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Gould</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Winter</surname> <given-names>PE</given-names></name>. <article-title>An insular outbreak of dengue hemorrhagic fever. II. virologic and serologic studies</article-title>. <source>Am J Trop Med Hyg</source>. <year>1968</year>;<volume>17</volume>: <fpage>600</fpage>–<lpage>608</lpage>. <object-id pub-id-type="pmid">4970512</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Buchy</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Vo</surname> <given-names>VL</given-names></name>, <name name-style="western"><surname>Bui</surname> <given-names>KT</given-names></name>, <name name-style="western"><surname>Trinh</surname> <given-names>TX</given-names></name>, <name name-style="western"><surname>Glaziou</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Le</surname> <given-names>TT</given-names></name>, <etal>et al</etal>. <article-title>Secondary dengue virus type 4 infections in vietnam</article-title>. <source>Southeast Asian J Trop Med Public Health</source>. <year>2005</year>;<volume>36</volume>: <fpage>178</fpage>–<lpage>185</lpage>. <object-id pub-id-type="pmid">15906664</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Halstead</surname> <given-names>SB</given-names></name>. <article-title>Dengue</article-title>. <source>The Lancet</source>. <year>2007</year>;<volume>370</volume>: <fpage>1644</fpage>–<lpage>1652</lpage>.</mixed-citation></ref>
<ref id="pntd.0003749.ref017"><label>17</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Murphy</surname> <given-names>BR</given-names></name>, <name name-style="western"><surname>Whitehead</surname> <given-names>SS</given-names></name>. <chapter-title>Immune response to dengue virus and prospects for a vaccine</chapter-title>. <source>Annu Rev Immunol</source>. <year>2011</year>;<volume>29</volume>: <fpage>587</fpage>–<lpage>619</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1146/annurev-immunol-031210-101315" xlink:type="simple">10.1146/annurev-immunol-031210-101315</ext-link></comment> <object-id pub-id-type="pmid">21219187</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wan</surname> <given-names>SW</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>CF</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>YH</given-names></name>, <name name-style="western"><surname>Yeh</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>HS</given-names></name>, <etal>et al</etal>. <article-title>Current progress in dengue vaccines</article-title>. <source>J Biomed Sci</source>. <year>2013</year>;<volume>20</volume>: 37-0127-20-37.</mixed-citation></ref>
<ref id="pntd.0003749.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guy</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Barrere</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Malinowski</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Saville</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Teyssou</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Lang</surname> <given-names>J</given-names></name>. <article-title>From research to phase III: Preclinical, industrial and clinical development of the sanofi pasteur tetravalent dengue vaccine</article-title>. <source>Vaccine</source>. <year>2011</year>;<volume>29</volume>: <fpage>7229</fpage>–<lpage>7241</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.vaccine.2011.06.094" xlink:type="simple">10.1016/j.vaccine.2011.06.094</ext-link></comment> <object-id pub-id-type="pmid">21745521</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dayan</surname> <given-names>GH</given-names></name>, <name name-style="western"><surname>Galan-Herrera</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Forrat</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Zambrano</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Bouckenooghe</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Harenberg</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naive adults in mexico</article-title>. <source>Hum Vaccin Immunother</source>. <year>2014</year>;<volume>10</volume>: <fpage>2853</fpage>–<lpage>2863</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4161/21645515.2014.972131" xlink:type="simple">10.4161/21645515.2014.972131</ext-link></comment> <object-id pub-id-type="pmid">25483647</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guy</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Nougarede</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Begue</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sanchez</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Souag</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Carre</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects</article-title>. <source>Vaccine</source>. <year>2008</year>;<volume>26</volume>: <fpage>5712</fpage>–<lpage>5721</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.vaccine.2008.08.019" xlink:type="simple">10.1016/j.vaccine.2008.08.019</ext-link></comment> <object-id pub-id-type="pmid">18762226</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Weiskopf</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Angelo</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>de Azeredo</surname> <given-names>EL</given-names></name>, <name name-style="western"><surname>Sidney</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Greenbaum</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Fernando</surname> <given-names>AN</given-names></name>, <etal>et al</etal>. <article-title>Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2013</year>;<volume>110</volume>: <fpage>E2046</fpage>–<lpage>53</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1305227110" xlink:type="simple">10.1073/pnas.1305227110</ext-link></comment> <object-id pub-id-type="pmid">23580623</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Balas</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Kennel</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Deauvieau</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Sodoyer</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Arnaud-Barbe</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Lang</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1–4 vaccine virus strains</article-title>. <source>J Infect Dis</source>. <year>2011</year>;<volume>203</volume>: <fpage>103</fpage>–<lpage>108</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/infdis/jiq022" xlink:type="simple">10.1093/infdis/jiq022</ext-link></comment> <object-id pub-id-type="pmid">21148502</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>da Costa</surname> <given-names>VG</given-names></name>, <name name-style="western"><surname>Marques-Silva</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Floriano</surname> <given-names>VG</given-names></name>, <name name-style="western"><surname>Moreli</surname> <given-names>ML</given-names></name>. <article-title>Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: A meta-analysis of randomized trials</article-title>. <source>Vaccine</source>. <year>2014</year>;<volume>32</volume>: <fpage>4885</fpage>–<lpage>4892</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.vaccine.2014.07.008" xlink:type="simple">10.1016/j.vaccine.2014.07.008</ext-link></comment> <object-id pub-id-type="pmid">25045816</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sabchareon</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Wallace</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Sirivichayakul</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Limkittikul</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Chanthavanich</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Suvannadabba</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in thai schoolchildren: A randomised, controlled phase 2b trial</article-title>. <source>Lancet</source>. <year>2012</year>;<volume>380</volume>: <fpage>1559</fpage>–<lpage>1567</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(12)61428-7" xlink:type="simple">10.1016/S0140-6736(12)61428-7</ext-link></comment> <object-id pub-id-type="pmid">22975340</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Villar</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Rivera-Medina</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Arredondo-Garcia</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Boaz</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Starr-Spires</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Thakur</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9–16 year olds: A randomized, controlled, phase II trial in latin america</article-title>. <source>Pediatr Infect Dis J</source>. <year>2013</year>;<volume>32</volume>: <fpage>1102</fpage>–<lpage>1109</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/INF.0b013e31829b8022" xlink:type="simple">10.1097/INF.0b013e31829b8022</ext-link></comment> <object-id pub-id-type="pmid">24067553</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Capeding</surname> <given-names>MR</given-names></name>, <name name-style="western"><surname>Tran</surname> <given-names>NH</given-names></name>, <name name-style="western"><surname>Hadinegoro</surname> <given-names>SR</given-names></name>, <name name-style="western"><surname>Ismail</surname> <given-names>HI</given-names></name>, <name name-style="western"><surname>Chotpitayasunondh</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Chua</surname> <given-names>MN</given-names></name>, <etal>et al</etal>. <article-title>Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in asia: A phase 3, randomised, observer-masked, placebo-controlled trial</article-title>. <source>Lancet</source>. <year>2014</year>;<volume>384</volume>: <fpage>1358</fpage>–<lpage>1365</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(14)61060-6" xlink:type="simple">10.1016/S0140-6736(14)61060-6</ext-link></comment> <object-id pub-id-type="pmid">25018116</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Villar</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Dayan</surname> <given-names>GH</given-names></name>, <name name-style="western"><surname>Arredondo-Garcia</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Rivera</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Cunha</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Deseda</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Efficacy of a tetravalent dengue vaccine in children in latin america</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>(<issue>1</issue>): <fpage>113</fpage>–<lpage>123</lpage>.</mixed-citation></ref>
<ref id="pntd.0003749.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wilder-Smith</surname> <given-names>A</given-names></name>. <article-title>Dengue vaccines: Dawning at last?</article-title> <source>Lancet</source>. <year>2014</year>;<volume>384</volume>: <fpage>1327</fpage>–<lpage>1329</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(14)61142-9" xlink:type="simple">10.1016/S0140-6736(14)61142-9</ext-link></comment> <object-id pub-id-type="pmid">25018119</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sabin</surname> <given-names>AB</given-names></name>. <article-title>The dengue group of viruses and its family relationships</article-title>. <source>Bacteriol Rev</source>. <year>1950</year>;<volume>14</volume>: <fpage>225</fpage>–<lpage>232</lpage>. <object-id pub-id-type="pmid">14772197</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Snow</surname> <given-names>GE</given-names></name>, <name name-style="western"><surname>Haaland</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Ooi</surname> <given-names>EE</given-names></name>, <name name-style="western"><surname>Gubler</surname> <given-names>DJ</given-names></name>. <article-title>Review article: Research on dengue during world war II revisited</article-title>. <source>Am J Trop Med Hyg</source>. <year>2014</year>;<volume>91</volume>: <fpage>1203</fpage>–<lpage>1217</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4269/ajtmh.14-0132" xlink:type="simple">10.4269/ajtmh.14-0132</ext-link></comment> <object-id pub-id-type="pmid">25311700</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yamanaka</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tabuchi</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Mulyatno</surname> <given-names>KC</given-names></name>, <name name-style="western"><surname>Susilowati</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Hendrianto</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Soegijanto</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Dengue virus infection-enhancing and neutralizing antibody balance in children of the philippines and indonesia</article-title>. <source>Microbes Infect</source>. <year>2012</year>;<volume>14</volume>: <fpage>1152</fpage>–<lpage>1159</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.micinf.2012.07.013" xlink:type="simple">10.1016/j.micinf.2012.07.013</ext-link></comment> <object-id pub-id-type="pmid">22841680</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Anderson</surname> <given-names>KB</given-names></name>, <name name-style="western"><surname>Gibbons</surname> <given-names>RV</given-names></name>, <name name-style="western"><surname>Cummings</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Nisalak</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Green</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Libraty</surname> <given-names>DH</given-names></name>, <etal>et al</etal>. <article-title>A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in thailand</article-title>. <source>J Infect Dis</source>. <year>2014</year>;<volume>209</volume>: <fpage>360</fpage>–<lpage>368</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/infdis/jit436" xlink:type="simple">10.1093/infdis/jit436</ext-link></comment> <object-id pub-id-type="pmid">23964110</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Montoya</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Gresh</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Mercado</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Williams</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>Vargas</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Gutierrez</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2013</year>;<volume>7</volume>: <fpage>e2357</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pntd.0002357" xlink:type="simple">10.1371/journal.pntd.0002357</ext-link></comment> <object-id pub-id-type="pmid">23951377</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref035"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Sharp TM, Hunsperger E, Munoz-Jordan JL, Margolis HS, Tomashek KM. Sequential episodes of dengue-puerto rico, 2005–2010. Am J Trop Med Hyg. 2014.</mixed-citation></ref>
<ref id="pntd.0003749.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mongkolsapaya</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Dejnirattisai</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>XN</given-names></name>, <name name-style="western"><surname>Vasanawathana</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Tangthawornchaikul</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Chairunsri</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever</article-title>. <source>Nat Med</source>. <year>2003</year>;<volume>9</volume>: <fpage>921</fpage>–<lpage>927</lpage>. <object-id pub-id-type="pmid">12808447</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Midgley</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Bajwa-Joseph</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Vasanawathana</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Limpitikul</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Wills</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Flanagan</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>An in-depth analysis of original antigenic sin in dengue virus infection</article-title>. <source>J Virol</source>. <year>2011</year>;<volume>85</volume>: <fpage>410</fpage>–<lpage>421</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.01826-10" xlink:type="simple">10.1128/JVI.01826-10</ext-link></comment> <object-id pub-id-type="pmid">20980526</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gwinn</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Sun</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Innis</surname> <given-names>BL</given-names></name>, <name name-style="western"><surname>Caudill</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>King</surname> <given-names>AD</given-names></name>. <article-title>Serotype-specific T(H)1 responses in recipients of two doses of candidate live-attenuated dengue virus vaccines</article-title>. <source>Am J Trop Med Hyg</source>. <year>2003</year>;<volume>69</volume>: <fpage>39</fpage>–<lpage>47</lpage>. <object-id pub-id-type="pmid">14740954</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mathew</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kurane</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Rothman</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>Zeng</surname> <given-names>LL</given-names></name>, <name name-style="western"><surname>Brinton</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Ennis</surname> <given-names>FA</given-names></name>. <article-title>Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a</article-title>. <source>J Clin Invest</source>. <year>1996</year>;<volume>98</volume>: <fpage>1684</fpage>–<lpage>1691</lpage>. <object-id pub-id-type="pmid">8833919</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Weiskopf</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Angelo</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Bangs</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Sidney</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Paul</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Peters</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes</article-title>. <source>J Virol</source>. <year>2015</year>;<volume>89</volume>: <fpage>120</fpage>–<lpage>128</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.02129-14" xlink:type="simple">10.1128/JVI.02129-14</ext-link></comment> <object-id pub-id-type="pmid">25320311</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Harenberg</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Begue</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Mamessier</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Gimenez-Fourage</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ching Seah</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Wei Liang</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in singapore</article-title>. <source>Hum Vaccin Immunother</source>. <year>2013</year>;<volume>9</volume>: <fpage>2317</fpage>–<lpage>2325</lpage>. <object-id pub-id-type="pmid">23839107</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zompi</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Montoya</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Pohl</surname> <given-names>MO</given-names></name>, <name name-style="western"><surname>Balmaseda</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Harris</surname> <given-names>E</given-names></name>. <article-title>Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2012</year>;<volume>6</volume>: <fpage>e1568</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pntd.0001568" xlink:type="simple">10.1371/journal.pntd.0001568</ext-link></comment> <object-id pub-id-type="pmid">22448292</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mathew</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>West</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kalayanarooj</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Gibbons</surname> <given-names>RV</given-names></name>, <name name-style="western"><surname>Srikiatkhachorn</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Green</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>B-cell responses during primary and secondary dengue virus infections in humans</article-title>. <source>J Infect Dis</source>. <year>2011</year>;<volume>204</volume>: <fpage>1514</fpage>–<lpage>1522</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/infdis/jir607" xlink:type="simple">10.1093/infdis/jir607</ext-link></comment> <object-id pub-id-type="pmid">21930609</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>de Alwis</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Williams</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>Schmid</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Lai</surname> <given-names>CY</given-names></name>, <name name-style="western"><surname>Patel</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>SA</given-names></name>, <etal>et al</etal>. <article-title>Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera</article-title>. <source>PLoS Pathog</source>. <year>2014</year>;<volume>10</volume>: <fpage>e1004386</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.ppat.1004386" xlink:type="simple">10.1371/journal.ppat.1004386</ext-link></comment> <object-id pub-id-type="pmid">25275316</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tsai</surname> <given-names>WY</given-names></name>, <name name-style="western"><surname>Lai</surname> <given-names>CY</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>YC</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>HE</given-names></name>, <name name-style="western"><surname>Edwards</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Jumnainsong</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection</article-title>. <source>J Virol</source>. <year>2013</year>;<volume>87</volume>: <fpage>12562</fpage>–<lpage>12575</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.00871-13" xlink:type="simple">10.1128/JVI.00871-13</ext-link></comment> <object-id pub-id-type="pmid">24027331</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lai</surname> <given-names>CY</given-names></name>, <name name-style="western"><surname>Williams</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>YC</given-names></name>, <name name-style="western"><surname>Knight</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Balmaseda</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Harris</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in nicaraguan dengue cases</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2013</year>;<volume>7</volume>: <fpage>e2451</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pntd.0002451" xlink:type="simple">10.1371/journal.pntd.0002451</ext-link></comment> <object-id pub-id-type="pmid">24069496</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kliks</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Nimmanitya</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Nisalak</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Burke</surname> <given-names>DS</given-names></name>. <article-title>Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants</article-title>. <source>Am J Trop Med Hyg</source>. <year>1988</year>;<volume>38</volume>: <fpage>411</fpage>–<lpage>419</lpage>. <object-id pub-id-type="pmid">3354774</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Halstead</surname> <given-names>SB</given-names></name>, <name name-style="western"><surname>O'Rourke</surname> <given-names>EJ</given-names></name>. <article-title>Dengue viruses and mononuclear phagocytes. I. infection enhancement by non-neutralizing antibody</article-title>. <source>J Exp Med</source>. <year>1977</year>;<volume>146</volume>: <fpage>201</fpage>–<lpage>217</lpage>. <object-id pub-id-type="pmid">406347</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vaughn</surname> <given-names>DW</given-names></name>, <name name-style="western"><surname>Green</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kalayanarooj</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Innis</surname> <given-names>BL</given-names></name>, <name name-style="western"><surname>Nimmannitya</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Suntayakorn</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity</article-title>. <source>J Infect Dis</source>. <year>2000</year>;<volume>181</volume>: <fpage>2</fpage>–<lpage>9</lpage>. <object-id pub-id-type="pmid">10608744</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moi</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Takasaki</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Saijo</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kurane</surname> <given-names>I</given-names></name>. <article-title>Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>2013</year>;<volume>107</volume>: <fpage>51</fpage>–<lpage>58</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/trstmh/trs007" xlink:type="simple">10.1093/trstmh/trs007</ext-link></comment> <object-id pub-id-type="pmid">23296697</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Flipse</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wilschut</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Smit</surname> <given-names>JM</given-names></name>. <article-title>Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans</article-title>. <source>Traffic</source>. <year>2013</year>;<volume>14</volume>: <fpage>25</fpage>–<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/tra.12012" xlink:type="simple">10.1111/tra.12012</ext-link></comment> <object-id pub-id-type="pmid">22998156</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rothman</surname> <given-names>AL</given-names></name>. <article-title>Immunity to dengue virus: A tale of original antigenic sin and tropical cytokine storms</article-title>. <source>Nat Rev Immunol</source>. <year>2011</year>;<volume>11</volume>: <fpage>532</fpage>–<lpage>543</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nri3014" xlink:type="simple">10.1038/nri3014</ext-link></comment> <object-id pub-id-type="pmid">21760609</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Halstead</surname> <given-names>SB</given-names></name>, <name name-style="western"><surname>Mahalingam</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Marovich</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Ubol</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Mosser</surname> <given-names>DM</given-names></name>. <article-title>Intrinsic antibody-dependent enhancement of microbial infection in macrophages: Disease regulation by immune complexes</article-title>. <source>Lancet Infect Dis</source>. <year>2010</year>;<volume>10</volume>: <fpage>712</fpage>–<lpage>722</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1473-3099(10)70166-3" xlink:type="simple">10.1016/S1473-3099(10)70166-3</ext-link></comment> <object-id pub-id-type="pmid">20883967</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Flamand</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Megret</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Mathieu</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Lepault</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Rey</surname> <given-names>FA</given-names></name>, <name name-style="western"><surname>Deubel</surname> <given-names>V</given-names></name>. <article-title>Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent fashion</article-title>. <source>J Virol</source>. <year>1999</year>;<volume>73</volume>: <fpage>6104</fpage>–<lpage>6110</lpage>. <object-id pub-id-type="pmid">10364366</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Falconar</surname> <given-names>AK</given-names></name>. <article-title>The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: Potential implications in haemorrhagic fever pathogenesis</article-title>. <source>Arch Virol</source>. <year>1997</year>;<volume>142</volume>: <fpage>897</fpage>–<lpage>916</lpage>. <object-id pub-id-type="pmid">9191856</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Avirutnan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Punyadee</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Manuyakorn</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Puttikhunt</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Kasinrerk</surname> <given-names>W</given-names></name>, <etal>et al</etal>. <article-title>Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E</article-title>. <source>PLoS Pathog</source>. <year>2007</year>;<volume>3</volume>: <fpage>e183</fpage>. <object-id pub-id-type="pmid">18052531</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref057"><label>57</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Beltramello</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Williams</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>Simmons</surname> <given-names>CP</given-names></name>, <name name-style="western"><surname>Macagno</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Simonelli</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Quyen</surname> <given-names>NT</given-names></name>, <etal>et al</etal>. <article-title>The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity</article-title>. <source>Cell Host Microbe</source>. <year>2010</year>;<volume>8</volume>: <fpage>271</fpage>–<lpage>283</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.chom.2010.08.007" xlink:type="simple">10.1016/j.chom.2010.08.007</ext-link></comment> <object-id pub-id-type="pmid">20833378</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref058"><label>58</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Smith</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Olivarez</surname> <given-names>NP</given-names></name>, <name name-style="western"><surname>Broadwater</surname> <given-names>AH</given-names></name>, <name name-style="western"><surname>de Silva</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Crowe</surname> <given-names>JE</given-names> <suffix>Jr</suffix></name>. <article-title>Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection</article-title>. <source>J Virol</source>. <year>2012</year>;<volume>86</volume>: <fpage>2665</fpage>–<lpage>2675</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.06335-11" xlink:type="simple">10.1128/JVI.06335-11</ext-link></comment> <object-id pub-id-type="pmid">22171265</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref059"><label>59</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Setthapramote</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Sasaki</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Puiprom</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Limkittikul</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Pitaksajjakul</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Pipattanaboon</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2012</year>;<volume>423</volume>: <fpage>867</fpage>–<lpage>872</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbrc.2012.06.057" xlink:type="simple">10.1016/j.bbrc.2012.06.057</ext-link></comment> <object-id pub-id-type="pmid">22713454</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref060"><label>60</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Heinz</surname> <given-names>FX</given-names></name>, <name name-style="western"><surname>Mandl</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Berger</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Tuma</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Kunz</surname> <given-names>C</given-names></name>. <article-title>Antibody-induced conformational changes result in enhanced avidity of antibodies to different antigenic sites on the tick-borne encephalitis virus glycoprotein</article-title>. <source>Virology</source>. <year>1984</year>;<volume>133</volume>: <fpage>25</fpage>–<lpage>34</lpage>. <object-id pub-id-type="pmid">6199892</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref061"><label>61</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Henchal</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>McCown</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Burke</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Seguin</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Brandt</surname> <given-names>WE</given-names></name>. <article-title>Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies</article-title>. <source>Am J Trop Med Hyg</source>. <year>1985</year>;<volume>34</volume>: <fpage>162</fpage>–<lpage>169</lpage>. <object-id pub-id-type="pmid">2578750</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref062"><label>62</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Monath</surname> <given-names>TP</given-names></name>, <name name-style="western"><surname>Wands</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Hill</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Gentry</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>Gubler</surname> <given-names>DJ</given-names></name>. <article-title>Multisite monoclonal immunoassay for dengue viruses: Detection of viraemic human sera and interference by heterologous antibody</article-title>. <source>J Gen Virol</source>. <year>1986</year>;<volume>67</volume> (Pt <issue>4</issue>): <fpage>639</fpage>–<lpage>650</lpage>.</mixed-citation></ref>
<ref id="pntd.0003749.ref063"><label>63</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Konishi</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Ajiro</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Nukuzuma</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Mason</surname> <given-names>PW</given-names></name>, <name name-style="western"><surname>Kurane</surname> <given-names>I</given-names></name>. <article-title>Comparison of protective efficacies of plasmid DNAs encoding japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice</article-title>. <source>Vaccine</source>. <year>2003</year>;<volume>21</volume>: <fpage>3675</fpage>–<lpage>3683</lpage>. <object-id pub-id-type="pmid">12922097</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref064"><label>64</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Putnak</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Fuller</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>VanderZanden</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Innis</surname> <given-names>BL</given-names></name>, <name name-style="western"><surname>Vaughn</surname> <given-names>DW</given-names></name>. <article-title>Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes</article-title>. <source>Am J Trop Med Hyg</source>. <year>2003</year>;<volume>68</volume>: <fpage>469</fpage>–<lpage>476</lpage>. <object-id pub-id-type="pmid">12875299</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref065"><label>65</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Henchal</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>Henchal</surname> <given-names>LS</given-names></name>, <name name-style="western"><surname>Schlesinger</surname> <given-names>JJ</given-names></name>. <article-title>Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus</article-title>. <source>J Gen Virol</source>. <year>1988</year>;<volume>69</volume> (Pt <issue>8</issue>): <fpage>2101</fpage>–<lpage>2107</lpage>. <object-id pub-id-type="pmid">3404125</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref066"><label>66</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Smith</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>de Alwis</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Kose</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Durbin</surname> <given-names>AP</given-names></name>, <name name-style="western"><surname>Whitehead</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>de Silva</surname> <given-names>AM</given-names></name>, <etal>et al</etal>. <article-title>Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics</article-title>. <source>J Infect Dis</source>. <year>2013</year>;<volume>207</volume>: <fpage>1898</fpage>–<lpage>1908</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/infdis/jit119" xlink:type="simple">10.1093/infdis/jit119</ext-link></comment> <object-id pub-id-type="pmid">23526830</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref067"><label>67</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dejnirattisai</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Jumnainsong</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Onsirisakul</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Fitton</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Vasanawathana</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Limpitikul</surname> <given-names>W</given-names></name>, <etal>et al</etal>. <article-title>Cross-reacting antibodies enhance dengue virus infection in humans</article-title>. <source>Science</source>. <year>2010</year>;<volume>328</volume>: <fpage>745</fpage>–<lpage>748</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1185181" xlink:type="simple">10.1126/science.1185181</ext-link></comment> <object-id pub-id-type="pmid">20448183</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref068"><label>68</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>de Alwis</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Beltramello</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Messer</surname> <given-names>WB</given-names></name>, <name name-style="western"><surname>Sukupolvi-Petty</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Wahala</surname> <given-names>WM</given-names></name>, <name name-style="western"><surname>Kraus</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2011</year>;<volume>5</volume>: <fpage>e1188</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pntd.0001188" xlink:type="simple">10.1371/journal.pntd.0001188</ext-link></comment> <object-id pub-id-type="pmid">21713020</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref069"><label>69</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>de Alwis</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Olivarez</surname> <given-names>NP</given-names></name>, <name name-style="western"><surname>Messer</surname> <given-names>WB</given-names></name>, <name name-style="western"><surname>Huynh</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Wahala</surname> <given-names>WM</given-names></name>, <etal>et al</etal>. <article-title>Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2012</year>;<volume>109</volume>: <fpage>7439</fpage>–<lpage>7444</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1200566109" xlink:type="simple">10.1073/pnas.1200566109</ext-link></comment> <object-id pub-id-type="pmid">22499787</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref070"><label>70</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rodenhuis-Zybert</surname> <given-names>IA</given-names></name>, <name name-style="western"><surname>van der Schaar</surname> <given-names>HM</given-names></name>, <name name-style="western"><surname>da Silva Voorham</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>van der Ende-Metselaar</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Lei</surname> <given-names>HY</given-names></name>, <name name-style="western"><surname>Wilschut</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Immature dengue virus: A veiled pathogen?</article-title> <source>PLoS Pathog</source>. <year>2010</year>;<volume>6</volume>: <fpage>e1000718</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.ppat.1000718" xlink:type="simple">10.1371/journal.ppat.1000718</ext-link></comment> <object-id pub-id-type="pmid">20062797</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref071"><label>71</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rodenhuis-Zybert</surname> <given-names>IA</given-names></name>, <name name-style="western"><surname>da Silva Voorham</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Torres</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>van de Pol</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Smit</surname> <given-names>JM</given-names></name>. <article-title>Antibodies against immature virions are not a discriminating factor for dengue disease severity</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2015</year>;<volume>9</volume>: <fpage>e0003564</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pntd.0003564" xlink:type="simple">10.1371/journal.pntd.0003564</ext-link></comment> <object-id pub-id-type="pmid">25760350</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref072"><label>72</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Endy</surname> <given-names>TP</given-names></name>, <name name-style="western"><surname>Nisalak</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Chunsuttitwat</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Vaughn</surname> <given-names>DW</given-names></name>, <name name-style="western"><surname>Green</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ennis</surname> <given-names>FA</given-names></name>, <etal>et al</etal>. <article-title>Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in thailand</article-title>. <source>J Infect Dis</source>. <year>2004</year>;<volume>189</volume>: <fpage>990</fpage>–<lpage>1000</lpage>. <object-id pub-id-type="pmid">14999601</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref073"><label>73</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lai</surname> <given-names>CY</given-names></name>, <name name-style="western"><surname>Tsai</surname> <given-names>WY</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>SR</given-names></name>, <name name-style="western"><surname>Kao</surname> <given-names>CL</given-names></name>, <name name-style="western"><surname>Hu</surname> <given-names>HP</given-names></name>, <name name-style="western"><surname>King</surname> <given-names>CC</given-names></name>, <etal>et al</etal>. <article-title>Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II</article-title>. <source>J Virol</source>. <year>2008</year>;<volume>82</volume>: <fpage>6631</fpage>–<lpage>6643</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.00316-08" xlink:type="simple">10.1128/JVI.00316-08</ext-link></comment> <object-id pub-id-type="pmid">18448542</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref074"><label>74</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Crill</surname> <given-names>WD</given-names></name>, <name name-style="western"><surname>Hughes</surname> <given-names>HR</given-names></name>, <name name-style="western"><surname>Delorey</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>GJ</given-names></name>. <article-title>Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens</article-title>. <source>PLoS One</source>. <year>2009</year>;<volume>4</volume>: <fpage>e4991</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0004991" xlink:type="simple">10.1371/journal.pone.0004991</ext-link></comment> <object-id pub-id-type="pmid">19337372</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref075"><label>75</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Crill</surname> <given-names>WD</given-names></name>, <name name-style="western"><surname>Roehrig</surname> <given-names>JT</given-names></name>. <article-title>Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to vero cells</article-title>. <source>J Virol</source>. <year>2001</year>;<volume>75</volume>: <fpage>7769</fpage>–<lpage>7773</lpage>. <object-id pub-id-type="pmid">11462053</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref076"><label>76</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sukupolvi-Petty</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Austin</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Purtha</surname> <given-names>WE</given-names></name>, <name name-style="western"><surname>Oliphant</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Nybakken</surname> <given-names>GE</given-names></name>, <name name-style="western"><surname>Schlesinger</surname> <given-names>JJ</given-names></name>, <etal>et al</etal>. <article-title>Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes</article-title>. <source>J Virol</source>. <year>2007</year>;<volume>81</volume>: <fpage>12816</fpage>–<lpage>12826</lpage>. <object-id pub-id-type="pmid">17881453</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref077"><label>77</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moreland</surname> <given-names>NJ</given-names></name>, <name name-style="western"><surname>Susanto</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Lim</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Tay</surname> <given-names>MY</given-names></name>, <name name-style="western"><surname>Rajamanonmani</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Hanson</surname> <given-names>BJ</given-names></name>, <etal>et al</etal>. <article-title>Phage display approaches for the isolation of monoclonal antibodies against dengue virus envelope domain III from human and mouse derived libraries</article-title>. <source>Int J Mol Sci</source>. <year>2012</year>;<volume>13</volume>: <fpage>2618</fpage>–<lpage>2635</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3390/ijms13032618" xlink:type="simple">10.3390/ijms13032618</ext-link></comment> <object-id pub-id-type="pmid">22489114</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref078"><label>78</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jarmer</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Zlatkovic</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Tsouchnikas</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Vratskikh</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Strauss</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Aberle</surname> <given-names>JH</given-names></name>, <etal>et al</etal>. <article-title>Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination</article-title>. <source>J Virol</source>. <year>2014</year>;<volume>88</volume>: <fpage>13845</fpage>–<lpage>13857</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.02086-14" xlink:type="simple">10.1128/JVI.02086-14</ext-link></comment> <object-id pub-id-type="pmid">25253341</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref079"><label>79</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Oliphant</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Nybakken</surname> <given-names>GE</given-names></name>, <name name-style="western"><surname>Austin</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Bramson</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Loeb</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Induction of epitope-specific neutralizing antibodies against west nile virus</article-title>. <source>J Virol</source>. <year>2007</year>;<volume>81</volume>: <fpage>11828</fpage>–<lpage>11839</lpage>. <object-id pub-id-type="pmid">17715236</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref080"><label>80</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vratskikh</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Stiasny</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Zlatkovic</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Tsouchnikas</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Jarmer</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Karrer</surname> <given-names>U</given-names></name>, <etal>et al</etal>. <article-title>Dissection of antibody specificities induced by yellow fever vaccination</article-title>. <source>PLoS Pathog</source>. <year>2013</year>;<volume>9</volume>: <fpage>e1003458</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.ppat.1003458" xlink:type="simple">10.1371/journal.ppat.1003458</ext-link></comment> <object-id pub-id-type="pmid">23818856</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref081"><label>81</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wahala</surname> <given-names>WM</given-names></name>, <name name-style="western"><surname>Kraus</surname> <given-names>AA</given-names></name>, <name name-style="western"><surname>Haymore</surname> <given-names>LB</given-names></name>, <name name-style="western"><surname>Accavitti-Loper</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>de Silva</surname> <given-names>AM</given-names></name>. <article-title>Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody</article-title>. <source>Virology</source>. <year>2009</year>;<volume>392</volume>: <fpage>103</fpage>–<lpage>113</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.virol.2009.06.037" xlink:type="simple">10.1016/j.virol.2009.06.037</ext-link></comment> <object-id pub-id-type="pmid">19631955</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref082"><label>82</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wahala</surname> <given-names>WM</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Butrapet</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>White</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>de Silva</surname> <given-names>AM</given-names></name>. <article-title>Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera</article-title>. <source>J Virol</source>. <year>2012</year>;<volume>86</volume>: <fpage>4019</fpage>–<lpage>4023</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.06871-11" xlink:type="simple">10.1128/JVI.06871-11</ext-link></comment> <object-id pub-id-type="pmid">22278250</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref083"><label>83</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dejnirattisai</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Wongwiwat</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Supasa</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Dai</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Rouvinsky</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus</article-title>. <source>Nat Immunol</source>. <year>2015</year>;<volume>16</volume>: <fpage>170</fpage>–<lpage>177</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ni.3058" xlink:type="simple">10.1038/ni.3058</ext-link></comment> <object-id pub-id-type="pmid">25501631</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref084"><label>84</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Teoh</surname> <given-names>EP</given-names></name>, <name name-style="western"><surname>Kukkaro</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Teo</surname> <given-names>EW</given-names></name>, <name name-style="western"><surname>Lim</surname> <given-names>AP</given-names></name>, <name name-style="western"><surname>Tan</surname> <given-names>TT</given-names></name>, <name name-style="western"><surname>Yip</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>The structural basis for serotype-specific neutralization of dengue virus by a human antibody</article-title>. <source>Sci Transl Med</source>. <year>2012</year>;<volume>4</volume>: 139ra83.</mixed-citation></ref>
<ref id="pntd.0003749.ref085"><label>85</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Messer</surname> <given-names>WB</given-names></name>, <name name-style="western"><surname>de Alwis</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Yount</surname> <given-names>BL</given-names></name>, <name name-style="western"><surname>Royal</surname> <given-names>SR</given-names></name>, <name name-style="western"><surname>Huynh</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>SA</given-names></name>, <etal>et al</etal>. <article-title>Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2014</year>;<volume>111</volume>: <fpage>1939</fpage>–<lpage>1944</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1317350111" xlink:type="simple">10.1073/pnas.1317350111</ext-link></comment> <object-id pub-id-type="pmid">24385585</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref086"><label>86</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Smith</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>de Alwis</surname> <given-names>AR</given-names></name>, <name name-style="western"><surname>Kose</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Jadi</surname> <given-names>RS</given-names></name>, <name name-style="western"><surname>de Silva</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Crowe</surname> <given-names>JE</given-names> <suffix>Jr</suffix></name>. <article-title>Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones</article-title>. <source>J Virol</source>. <year>2014</year>;<volume>88</volume>: <fpage>12233</fpage>–<lpage>12241</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.00247-14" xlink:type="simple">10.1128/JVI.00247-14</ext-link></comment> <object-id pub-id-type="pmid">25100837</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref087"><label>87</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Weiskopf</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Sette</surname> <given-names>A</given-names></name>. <article-title>T-cell immunity to infection with dengue virus in humans</article-title>. <source>Front Immunol</source>. <year>2014</year>;<volume>5</volume>: <fpage>93</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3389/fimmu.2014.00093" xlink:type="simple">10.3389/fimmu.2014.00093</ext-link></comment> <object-id pub-id-type="pmid">24639680</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref088"><label>88</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sanchez</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Gimenez</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Tomlinson</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Chan</surname> <given-names>PK</given-names></name>, <name name-style="western"><surname>Thomas</surname> <given-names>GN</given-names></name>, <name name-style="western"><surname>Forrat</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in vero cells (VDV3)</article-title>. <source>Vaccine</source>. <year>2006</year>;<volume>24</volume>: <fpage>4914</fpage>–<lpage>4926</lpage>. <object-id pub-id-type="pmid">16632108</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref089"><label>89</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mongkolsapaya</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Duangchinda</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Dejnirattisai</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Vasanawathana</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Avirutnan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Jairungsri</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>T cell responses in dengue hemorrhagic fever: Are cross-reactive T cells suboptimal?</article-title> <source>J Immunol</source>. <year>2006</year>;<volume>176</volume>: <fpage>3821</fpage>–<lpage>3829</lpage>. <object-id pub-id-type="pmid">16517753</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref090"><label>90</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mangada</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Rothman</surname> <given-names>AL</given-names></name>. <article-title>Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes</article-title>. <source>J Immunol</source>. <year>2005</year>;<volume>175</volume>: <fpage>2676</fpage>–<lpage>2683</lpage>. <object-id pub-id-type="pmid">16081844</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref091"><label>91</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shresta</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kyle</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Snider</surname> <given-names>HM</given-names></name>, <name name-style="western"><surname>Basavapatna</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Beatty</surname> <given-names>PR</given-names></name>, <name name-style="western"><surname>Harris</surname> <given-names>E</given-names></name>. <article-title>Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical</article-title>. <source>J Virol</source>. <year>2004</year>;<volume>78</volume>: <fpage>2701</fpage>–<lpage>2710</lpage>. <object-id pub-id-type="pmid">14990690</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref092"><label>92</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zellweger</surname> <given-names>RM</given-names></name>, <name name-style="western"><surname>Miller</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Eddy</surname> <given-names>WE</given-names></name>, <name name-style="western"><surname>White</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Johnston</surname> <given-names>RE</given-names></name>, <name name-style="western"><surname>Shresta</surname> <given-names>S</given-names></name>. <article-title>Role of humoral versus cellular responses induced by a protective dengue vaccine candidate</article-title>. <source>PLoS Pathog</source>. <year>2013</year>;<volume>9</volume>: <fpage>e1003723</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.ppat.1003723" xlink:type="simple">10.1371/journal.ppat.1003723</ext-link></comment> <object-id pub-id-type="pmid">24204271</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref093"><label>93</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. WHO/IVB/07 07. 2007.</mixed-citation></ref>
<ref id="pntd.0003749.ref094"><label>94</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Plotkin</surname> <given-names>SA</given-names></name>. <article-title>Correlates of protection induced by vaccination</article-title>. <source>Clin Vaccine Immunol</source>. <year>2010</year>;<volume>17</volume>: <fpage>1055</fpage>–<lpage>1065</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/CVI.00131-10" xlink:type="simple">10.1128/CVI.00131-10</ext-link></comment> <object-id pub-id-type="pmid">20463105</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref095"><label>95</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Thomas</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Nisalak</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Anderson</surname> <given-names>KB</given-names></name>, <name name-style="western"><surname>Libraty</surname> <given-names>DH</given-names></name>, <name name-style="western"><surname>Kalayanarooj</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Vaughn</surname> <given-names>DW</given-names></name>, <etal>et al</etal>. <article-title>Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance</article-title>. <source>Am J Trop Med Hyg</source>. <year>2009</year>;<volume>81</volume>: <fpage>825</fpage>–<lpage>833</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4269/ajtmh.2009.08-0625" xlink:type="simple">10.4269/ajtmh.2009.08-0625</ext-link></comment> <object-id pub-id-type="pmid">19861618</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref096"><label>96</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rainwater-Lovett</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Rodriguez-Barraquer</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Cummings</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Lessler</surname> <given-names>J</given-names></name>. <article-title>Variation in dengue virus plaque reduction neutralization testing: Systematic review and pooled analysis</article-title>. <source>BMC Infect Dis</source>. <year>2012</year>;<volume>12</volume>: 233-2334-12-233.</mixed-citation></ref>
<ref id="pntd.0003749.ref097"><label>97</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Salje</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Rodriguez-Barraquer</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Rainwater-Lovett</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Nisalak</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Thaisomboonsuk</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Thomas</surname> <given-names>SJ</given-names></name>, <etal>et al</etal>. <article-title>Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2014</year>;<volume>8</volume>: <fpage>e2952</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pntd.0002952" xlink:type="simple">10.1371/journal.pntd.0002952</ext-link></comment> <object-id pub-id-type="pmid">24967885</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref098"><label>98</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dowd</surname> <given-names>KA</given-names></name>, <name name-style="western"><surname>Jost</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Durbin</surname> <given-names>AP</given-names></name>, <name name-style="western"><surname>Whitehead</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Pierson</surname> <given-names>TC</given-names></name>. <article-title>A dynamic landscape for antibody binding modulates antibody-mediated neutralization of west nile virus</article-title>. <source>PLoS Pathog</source>. <year>2011</year>;<volume>7</volume>: <fpage>e1002111</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.ppat.1002111" xlink:type="simple">10.1371/journal.ppat.1002111</ext-link></comment> <object-id pub-id-type="pmid">21738473</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref099"><label>99</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Smith</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>de Alwis</surname> <given-names>AR</given-names></name>, <name name-style="western"><surname>Kose</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Harris</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Ibarra</surname> <given-names>KD</given-names></name>, <name name-style="western"><surname>Kahle</surname> <given-names>KM</given-names></name>, <etal>et al</etal>. <article-title>The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein</article-title>. <source>MBio</source>. <year>2013</year>;<volume>4</volume>: <fpage>e00873</fpage>–<lpage>13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/mBio.00873-13" xlink:type="simple">10.1128/mBio.00873-13</ext-link></comment> <object-id pub-id-type="pmid">24255124</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref100"><label>100</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mahalingam</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Herring</surname> <given-names>BL</given-names></name>, <name name-style="western"><surname>Halstead</surname> <given-names>SB</given-names></name>. <article-title>Call to action for dengue vaccine failure</article-title>. <source>Emerg Infect Dis</source>. <year>2013</year>;<volume>19</volume>: <fpage>1335</fpage>–<lpage>1337</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3201/eid1908.121864" xlink:type="simple">10.3201/eid1908.121864</ext-link></comment> <object-id pub-id-type="pmid">23876389</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref101"><label>101</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Buddhari</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Aldstadt</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Endy</surname> <given-names>TP</given-names></name>, <name name-style="western"><surname>Srikiatkhachorn</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Thaisomboonsuk</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Klungthong</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2014</year>;<volume>8</volume>: <fpage>e3230</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pntd.0003230" xlink:type="simple">10.1371/journal.pntd.0003230</ext-link></comment> <object-id pub-id-type="pmid">25329173</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref102"><label>102</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Erra</surname> <given-names>EO</given-names></name>, <name name-style="western"><surname>Askling</surname> <given-names>HH</given-names></name>, <name name-style="western"><surname>Yoksan</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Rombo</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Riutta</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Vene</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Cross-protective capacity of japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes</article-title>. <source>Clin Infect Dis</source>. <year>2013</year>;<volume>56</volume>: <fpage>267</fpage>–<lpage>270</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cid/cis883" xlink:type="simple">10.1093/cid/cis883</ext-link></comment> <object-id pub-id-type="pmid">23074319</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref103"><label>103</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sirivichayakul</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Sabchareon</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Limkittikul</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Yoksan</surname> <given-names>S</given-names></name>. <article-title>Plaque reduction neutralization antibody test does not accurately predict protection against dengue infection in ratchaburi cohort, thailand</article-title>. <source>Virol J</source>. <year>2014</year>;<volume>11</volume>: 48-422X-11-48.</mixed-citation></ref>
<ref id="pntd.0003749.ref104"><label>104</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hss</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>Koh</surname> <given-names>MT</given-names></name>, <name name-style="western"><surname>Tan</surname> <given-names>KK</given-names></name>, <name name-style="western"><surname>Chan</surname> <given-names>LG</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Bouckenooghe</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11 years in malaysia: A randomized, placebo-controlled, phase III study</article-title>. <source>Vaccine</source>. <year>2013</year>;<volume>31</volume>: <fpage>5814</fpage>–<lpage>5821</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.vaccine.2013.10.013" xlink:type="simple">10.1016/j.vaccine.2013.10.013</ext-link></comment> <object-id pub-id-type="pmid">24135573</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref105"><label>105</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pierson</surname> <given-names>TC</given-names></name>, <name name-style="western"><surname>Fremont</surname> <given-names>DH</given-names></name>, <name name-style="western"><surname>Kuhn</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Diamond</surname> <given-names>MS</given-names></name>. <article-title>Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: Implications for vaccine development</article-title>. <source>Cell Host Microbe</source>. <year>2008</year>;<volume>4</volume>: <fpage>229</fpage>–<lpage>238</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.chom.2008.08.004" xlink:type="simple">10.1016/j.chom.2008.08.004</ext-link></comment> <object-id pub-id-type="pmid">18779049</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref106"><label>106</label><mixed-citation publication-type="other" xlink:type="simple">Corbett KS, Katzelnick L, Tissera H, Amerasinghe A, de Silva AD, de Silva AM. Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a sri lankan pediatric cohort. J Infect Dis. 2014.</mixed-citation></ref>
<ref id="pntd.0003749.ref107"><label>107</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rabaa</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Klungthong</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Yoon</surname> <given-names>IK</given-names></name>, <name name-style="western"><surname>Holmes</surname> <given-names>EC</given-names></name>, <name name-style="western"><surname>Chinnawirotpisan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Thaisomboonsuk</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Frequent in-migration and highly focal transmission of dengue viruses among children in kamphaeng phet, thailand</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2013</year>;<volume>7</volume>: <fpage>e1990</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pntd.0001990" xlink:type="simple">10.1371/journal.pntd.0001990</ext-link></comment> <object-id pub-id-type="pmid">23350000</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref108"><label>108</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Caron</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Grard</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Paupy</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Mombo</surname> <given-names>IM</given-names></name>, <name name-style="western"><surname>Bikie</surname> <given-names>Bi Nso B</given-names></name>, <name name-style="western"><surname>Kassa</surname> <given-names>Kassa FR</given-names></name>, <etal>et al</etal>. <article-title>First evidence of simultaneous circulation of three different dengue virus serotypes in africa</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>: <fpage>e78030</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0078030" xlink:type="simple">10.1371/journal.pone.0078030</ext-link></comment> <object-id pub-id-type="pmid">24205075</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref109"><label>109</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Halstead</surname> <given-names>SB</given-names></name>. <article-title>Dengue vaccine development: A 75% solution?</article-title> <source>Lancet</source>. <year>2012</year>;<volume>380</volume>: <fpage>1535</fpage>–<lpage>1536</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(12)61510-4" xlink:type="simple">10.1016/S0140-6736(12)61510-4</ext-link></comment> <object-id pub-id-type="pmid">22975339</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref110"><label>110</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>XQ</given-names></name>, <name name-style="western"><surname>Qiu</surname> <given-names>LW</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wen</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Cai</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: Implications for dengue vaccine design</article-title>. <source>J Gen Virol</source>. <year>2013</year>;<volume>94</volume>: <fpage>2191</fpage>–<lpage>2201</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1099/vir.0.055178-0" xlink:type="simple">10.1099/vir.0.055178-0</ext-link></comment> <object-id pub-id-type="pmid">23851440</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref111"><label>111</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sessions</surname> <given-names>OM</given-names></name>, <name name-style="western"><surname>Tan</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Goh</surname> <given-names>KC</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Tan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Rozen</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Host cell transcriptome profile during wild-type and attenuated dengue virus infection</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2013</year>;<volume>7</volume>: <fpage>e2107</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pntd.0002107" xlink:type="simple">10.1371/journal.pntd.0002107</ext-link></comment> <object-id pub-id-type="pmid">23516652</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref112"><label>112</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guillot</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Otelea</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Delpeyroux</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Crainic</surname> <given-names>R</given-names></name>. <article-title>Point mutations involved in the attenuation/neurovirulence alternation in type 1 and 2 oral polio vaccine strains detected by site-specific polymerase chain reaction</article-title>. <source>Vaccine</source>. <year>1994</year>;<volume>12</volume>: <fpage>503</fpage>–<lpage>507</lpage>. <object-id pub-id-type="pmid">8036823</object-id></mixed-citation></ref>
<ref id="pntd.0003749.ref113"><label>113</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shimizu</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Thorley</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Paladin</surname> <given-names>FJ</given-names></name>, <name name-style="western"><surname>Brussen</surname> <given-names>KA</given-names></name>, <name name-style="western"><surname>Stambos</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Yuen</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Circulation of type 1 vaccine-derived poliovirus in the philippines in 2001</article-title>. <source>J Virol</source>. <year>2004</year>;<volume>78</volume>: <fpage>13512</fpage>–<lpage>13521</lpage>. <object-id pub-id-type="pmid">15564462</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>